US20020177856A1 - Intraocular implant, delivery device, and method of implantation - Google Patents
Intraocular implant, delivery device, and method of implantation Download PDFInfo
- Publication number
- US20020177856A1 US20020177856A1 US10/190,740 US19074002A US2002177856A1 US 20020177856 A1 US20020177856 A1 US 20020177856A1 US 19074002 A US19074002 A US 19074002A US 2002177856 A1 US2002177856 A1 US 2002177856A1
- Authority
- US
- United States
- Prior art keywords
- implant
- eyeball
- tube
- delivery device
- implanting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
Definitions
- the invention relates generally to ophthalmic implants for treatment of glaucoma, delivery devices for implanting such implants, and to methods of implanting such implants.
- Glaucoma is an eye condition characterized by an increase in the intraocular pressure (IOP) of the eye to an abnormal level.
- IOP intraocular pressure
- a normal eye maintains a proper IOP by the circulation within the eye of aqueous humor aqueous humor is secreted from the ciliary body, passes through the pupil into the anterior chamber of the eyeball, and is filtered out of the eyeball via the trabeculum and the Canal of Schlemm.
- the aqueous humor excretory pathway is blocked, the aqueous humor cannot pass out of the eyeball at an adequate rate, the IOP rises, the eyeball becomes harder, and the optic nerve atrophies by the pressure applied on its fibers leaving the retina.
- a characteristic optic neuropathy develops, resulting in progressive death of the ganglion cells in the retina, restriction of the visual field, and eventual blindness. Advanced stages of the disease are characterized also by significant pain.
- Glaucoma treatment it initiated early in the course of the disease, can prevent further deterioration and preserve most of the ocular functions.
- the goal of glaucoma treatment is to reduce the IOP to level which is considered safe for a particular eye, but which is not so low as to cause ocular malfunction or retinal complications.
- glaucoma treatment is filtration surgery, which provides an alternate route for aqueous humor to exit the anterior chamber of the eyeball and enter the sub-conjunctival space, thereby lowering the IOP.
- filtration surgery provides an alternate route for aqueous humor to exit the anterior chamber of the eyeball and enter the sub-conjunctival space, thereby lowering the IOP.
- full thickness operations a fistula is created through the limbal sclera, connecting directly the anterior chamber of the eyeball and the sub-conjunctival space.
- Full thickness operations provide long-lasting control of IOP; however, excessive loss of aqueous humor from the eyeball during the early postoperative period frequently leads to hypotony.
- trabeculectomy In guarded filtration surgery (trabeculectomy), a fistula created through the limbal sclera is protected by an overlying partial thickness sutured scleral flap.
- the scleral flap provides additional resistance to excessive loss of aqueous humor from the eyeball, thereby reducing the risk of early postoperative hypotony.
- trabeculectomy may result in higher eventual IOP and increased risk of late failure of filtration, compared with full thickness operations.
- a full thickness filtering fistula may be created by a holmium laser probe, with minimal surgically induced trauma. After retrobulbar anesthesia, a conjunctival incision (approximately 1 mm) is made about 12-15 mm posterior to the intended sclerostomy site, and a laser probe is advanced through the sub-conjunctival space to the limbus. Then, multiple laser pulses are applied until a full thickness fistula is created. This technique has sometimes resulted in early hypocony on account of a difficulty in controlling the sclerostomy size.
- Typical ophthalmic implants utilize drainage tubes so as to maintain the integrity of the openings formed in the eyeball for the relief of the IOP.
- Typical ophthalmic implants suffer from several disadvantages.
- the implants typically utilize a valve mechanism for regulating the flow of aqueous humor from the eyeball; defects in and/or failure of such valve mechanisms could lead to excessive loss of aqueous humor from the eyeball and possible hypotony.
- the implants also tend to clog over time, either from the inside by tissue, such as the iris, being sucked into the inlet, or from the outside by the proliferation of cells, for example by scarring.
- the typical implant insertion operation is complicated, costly and takes a long time.
- U.S. Pat. No. 3,788,327 to Donowitz et al. shows a prior art implant utilizing a valve mechanism for regulating the flow of aqueous humor from the eyeball.
- defects in and/or failure of such a valve mechanism could lead to excessive loss of aqueous humor from the eyeball and possible hypotony.
- both the inlet opening and the outlet opening in the implant shown in U.S. Pat. No. 3,788,327 may be susceptible to clogging—the inlet opening by the iris and the outlet opening by scarring.
- implantation of an implant according to U.S. Pat. No. 3,788,327 may involve the separate steps of first providing a tract for receiving the implant and/or suturing the implant once it is in place, which add time and possible complications to the operation.
- an intraocular implant is provided to be implanted in the eyeball.
- the implant includes a tube having an inlet end, an outlet end, and a tube passage therebetween for permitting aqueous humor to flow out of the eyeball, and a flanged disk connected to the tube at the outlet end of the cube.
- the cube passage has a cross-sectional area sufficiently small to inhibit the flow of aqueous humor through the tube passage when the IOP is below a threshold amount, thereby preventing the IOP from falling below its critical limit.
- the flanged disk which is designed to be located underneath the conjunctiva, may have an outer rim for forming a reservoir having an enlarged cross-sectional area relative to the cross-sectional area of the tube passage.
- the elasticity of the conjunctiva in conjunction with this design of the flanged disk assists in regulating the flow of aqueous humor through the tube as a function of the IOP.
- the tube at its inlet end may be provided with a beveled surface which faces away from the iris when the implant is inserted. Additionally, one or more circumferential holes may be provided along the tube for allowing aqueous humor to flow into the tube passage even if the axial inlet opening is blocked.
- the flanged disk may have an outer rim as described above which raises the conjunctiva away from the axial outlet of the tube passage to allow outflow.
- One or more inner uprights (which may be in the form of an inner rim) may also be provided on the flanged disk for this purpose. Clogging is further avoided by implanting the implant under the conjunctiva at a distance away from an insertion slit in the conjunctiva, such that healing of the slit does not cause scar tissue to form in the area of the axial outlet opening of the implant.
- the implant may have one or more retention projections (for example, in the form of a spur, flange, or plate).
- the retention projection may be rigid, or it may be made of an elastic material such that it is able to be flexed inward against the tube during penetration through the sclera.
- the retention projection may be designed to lie initially relatively flat against the tube for easier penetration through the sclera and to prevent tearing of the sclera, with a mechanism for extending the retention projection outwardly when the implant is implanted in the eyeball.
- the retention projection may be extended outwardly by a separate expansion tool or may be constructed of a shape memory alloy so that it is extended outwardly when subjected to the heat of the eyeball.
- One or more retention projections according to the invention are sufficient to reliably anchor the implant in the eyeball without the need for sutures, saving time and costs.
- Implantation may also be facilitated by the provision of one or more markers on the implant visible through the cornea upon passing through the sclera.
- a circumferential hole as described above may serve as a marker; alternatively, the marker may be some other suitable visible mechanism, such as a scratch or colored mark on the cube. The visibility of the marker lets the doctor know that the marker has passed through the sclera, indicating that the implant is in place.
- Implantation of an implant may be performed by use of a delivery device in accordance with the invention, comprising a handle and a rodlike instrument, for example a needle or probe, for carrying the implant for insertion into the eyeball.
- the delivery device has a tip for insertion into the tube passage of the implant and a suitable retention mechanism for preventing the implant from moving up the delivery device during implantation.
- the retention mechanism may also be constructed to prevent the implant from rotating during implantation to insure proper orientation of the implant in the eyeball.
- the delivery device may additionally have a suitable expansion tool for extending one or more retention projections of the implant outwardly once the projection or projections have penetrated through the sclera.
- a small slit is cut in a portion of the conjunctiva which normally lies at a distance away from the intended implantation site.
- the slit also may be very small, for example about 2 mm in length or less.
- the implant is placed through the slit, directed to the implantation site, and inserted into the sclera at the implantation site.
- the sclera may be pierced either by a needle-like tip of the tube of the implant formed by a beveled surface at the inlet end of the tube as described above or by the tip of a needle of the delivery device which carries the implant.
- the implant may be inserted directly into the eyeball without the need for any separate piercing step, resulting in cost and time savings.
- An intraocular implant, delivery device, and method of implantation according to the invention provide the advantages of a full thickness fistula, while avoiding the limitations of the standard trabeculectomy.
- An implant according to the invention may be very small and implantable without surgery. No surgery room or hospitalization is necessary, thereby reducing costs. Implantation is minimally invasive, simple and quick, requiring only local anesthesia. Retrobulbar anaesthesia is not necessary, and thus iatrogenic damage to the optic nerve is avoided There is no need to perform an iridectomy, and thus aqueous flow is maintained, lens nourishment is unaffected, and the likelihood of cataracts developing as a result of the procedure is reduced.
- FIG. 1 is a schematic cross-sectional view of a first embodiment of an intraocular implant according to the invention, shown inserted in an eyeball;
- FIG. 2 is an enlarged perspective view of the intraocular implant of FIG. 1;
- FIG. 3 is a view similar to FIG. 2, with part of the intraocular implant cut away to show a sectional view thereof;
- FIG. 4 is an enlarged perspective view of a disk portion of the intraocular implant of FIG. 1;
- FIGS. 5 through 7 illustrate the action of the conjunctiva during operation of the incraocular implant of FIG. 1;
- FIGS. 8 through 10 illustrate a delivery device and insertion of the intraocular implant of FIG. 1 into an eyeball
- FIG. 11 is an enlarged perspective view of a second embodiment of an intraocular implant according to the invention, with part of the intraocular implant cut away to show a sectional view thereof;
- FIG. 12 is a cop view of the incraocular implant of FIG. 11, showing a flanged disk portion of the implant;
- FIG. 13 illustrates a delivery device and insertion of the intraocular implant of FIG. 11 into an eyeball
- FIG. 14 is a schematic cross-sectional view of the intraocular implant of FIG. 11, shown inserted in an eyeball;
- FIGS. 15 and 16 illustrate a third embodiment of an intraocular implant according to the invention.
- FIG. 1 illustrates an intraocular implant 30 , constructed in accordance with an embodiment of the invention, implanted in an eyeball 10 .
- the implant 30 comprises a needle-like tube 32 and a flanged disk 34 .
- the plane of the flanged disk 34 forms an angle with the tube 32 chat corresponds to the angle between the surface of the sclera 12 and the axis of insertion of the implant 30 .
- the implant 30 is inserted in the sclera 12 of the eyeball 10 , in the limbal area 14 adjacent to the cornea 16 , and protrudes into the anterior chamber 20 adjacent the iris 22 .
- the implant 30 is inserted so that the flanged disk 34 is placed on a surface of the sclera 12 underneath the conjunctiva 18 .
- the implant 30 may be placed above or below the Tenon's capsule (not shown) It will be appreciated by persons of ordinary skill in the art that the exact location for inserting the implant 30 is not restricted to that shown, and may be any other suitable position, such as behind the iris 22 .
- FIG. 2 shows an enlarged perspective view of the implant 30 of FIG. 1, and FIG. 3 shows a similar view, with part of the implant 30 cut away.
- the tube 32 which may take the form of a modified standard retrobulbar tip, has an inlet end 40 , an outlet end 50 , and a tube passage 38 extending therebetween, with the tube passage 38 having an axial inlet 41 and an axial outlet 51 .
- the flanged disk 34 is connected to the tube 32 at its outlet end 50 .
- the entire implant is very small; for example the cube 32 may have a length of about 2 mm and a width of about 0.5 mm, and the flanged disk 34 may have a diameter of about 1 mm and a thickness of less that 0.1 mm.
- the tube passage 38 has a cross-sectional area sufficiently small to inhibit the flow of aqueous humor through the cube passage when the IOP of the eye is below a threshold amount, thereby preventing the IOP from falling below its critical limit.
- the cylindrical tube passage 38 has a diameter of 300 micrometers, such that an IOP of 5 mm Hg is needed for the aqueous humor to flow out.
- aqueous humor drains from the anterior chamber 20 of the eyeball 10 through the axial inlet 41 and one or more circumferential holes 72 , through the tube passage 38 , and into the space under the conjunctiva 18 .
- the circumferential holes 42 may take any suitable form; for example, they may be in the form of circular openings whose combined cross-sectional area is equal to the cross-sectional area of the tube passage 38 .
- the circumferential holes 42 prevent the tube passage 38 from becoming clogged at its inlet end because, even if the iris 22 obstructs the axial inlet 41 , aqueous humor can still pass through the circumferential holes 42 .
- the circumferential holes 42 also serve to cause a back pressure in the tube passage 38 to unclog the axial inlet 41 .
- the circumferential holes 42 serve the additional purpose of insuring a proper insertion depth of the implant 30 , as the upper hole is visible during implantation after penetration through the sclera and thus can be used as a marker.
- any other suitable marker such as a scratch or colored mark may be used.
- the inlet end 40 of the tube 32 has a needle-like tip formed by a beveled surface 36 , angled sharply for easy insertion into the eyeball.
- the beveled surface 36 increases the area of the axial inlet 41 to enlarge the entrance to the tube passage 38 .
- the beveled surface 36 is designed to face away from the iris 22 to reduce the possibility of obstruction of the axial inlet 41 . Because the flanged disk 34 is designed to rest against the sclera 14 and the beveled surface 36 is designed to face away from the iris 22 , the beveled-surface 36 lies in a plane which is angled opposite to the plane in which the flanged disk 34 lies.
- the tube 32 may have one or more retention projections in the form of one or more spurs 52 provided integrally with it for retaining the implant 30 in the eyeball 10 after insertion.
- the retention spur 52 may be made as a separate part connected to the tube 32 by, for example, welding or brazing.
- the retention spur 52 may be rigid, or it may be flexible such chat it bends coward the tube 32 during penetration of the sclera and springs outward to its original shape after passing through the sclera.
- the retention sour 52 may be designed for plastic deformation by a separate expansion tool (for example, a balloon) once it is in the eyeball 10 , or the retention spur 52 may be constructed of a shape memory alloy such that the spur is flat against the tube when cool but expands to its final shape when subjected to the heat of the eyeball 10 .
- the flanged disk 34 shown enlarged in FIG. 4, comprises a base 44 , an outer rim 46 , and a plurality of inner uprights 48 .
- the base 44 and outer rim 46 define a reservoir 54 such that, in operation, the aqueous humor flows out of the axial outlet 51 of the tube passage 38 , between the uprights 48 , and into the reservoir 54 .
- the enlarged cross-sectional area of the reservoir 54 as compared to the cross-sectional area of the tube passage 38 provides a larger area for absorption of the aqueous humor by the conjunctiva 18 and also acts in conjunction with the elasticity of the conjunctiva 18 to assist in regulating the flow of aqueous humor through the implant 30 as a function of the IOP.
- FIGS. 5 through 7 illustrate the action of the conjunctiva 18 during operation of the implant 30 , in which it can be seen that the aqueous humor which flows out of the tube passage forms a “bleb” 24 below the conjunctiva 18 . It will be appreciated by persons having ordinary skill in the art that a higher IOP results in a higher flow rate through the implant 30 , and a greater force of the aqueous humor on the conjunctiva 18 .
- the outer rim 46 of the flanged disk 34 serves the additional purpose of raising the conjunctiva 18 away from the axial outlet 51 to prevent clogging of the tube passage 38 .
- the inner uprights 48 also serve this purpose.
- the shape of the flanged disk 34 may be, but is not limited to, an ellipse, and it will be appreciated by persons having ordinary skill in the art that it may conform to any shape which allows the implant to fit under the conjunctiva 18 and which regulates the IOP.
- the size and/or shape of the flanged disk 34 and/or the angle between the flanged disk 34 and the tube 32 can also be changed in order to use different implants for different persons' eyes.
- FIGS. 8 through 10 illustrate a delivery device 60 and a method of inserting the intraocular implant 30 into an eyeball.
- the implant 30 is first attached to the delivery device 60 , having a handle 62 and a suitable rodlike instrument 64 such as a needle or probe.
- the rodlike instrument 64 has a tip 70 for penetrating a tube passage of the implant 30 and a retention mechanism for preventing the implant from moving up the delivery device during implantation, for example in the form of an abutment surface 68 having an angle generally corresponding to that of the flanged disk 34 .
- This configuration also prevents rotation of the implant 30 on the delivery device 60 , thereby insuring proper orientation of the implant in the eyeball.
- the retention mechanism may also include one or more projections for extending inside the outer rim and/or between the inner uprights on the flanged disk 34 .
- the retention mechanism may be the tip of the rodlike instrument, constructed to engage the inside of the tube passage of the implant with a friction fit, thereby preventing the implant from moving up the delivery device during implantation.
- a delivery device 60 in which the rodlike instrument is a needle 65 is illustrated in FIG. 9.
- the delivery device 60 is similar to a standard medical syringe having a housing and a needle 65 with a bore 67 .
- the front tip 69 of the needle 65 is configured as an abutment surface having an angle generally corresponding to that of the flanged disk 34 .
- the bore 67 of the needle 65 has a tip in the form of a plug 71 which is configured to have a cross-sectional shape corresponding to that of the tube passage 38 .
- the implant 30 is placed over the plug 71 , with the end of the plug 71 projecting into the tube passage 38 , and with the front tip 69 of the needle 65 abutting against the flanged disk 34 .
- the plug 71 blocks the tube passage 38 during implantation.
- a small slit 26 is cut in a portion of the conjunctiva 18 which normally lies at a distance away from a portion 28 of the conjunctiva 18 which normally covers the intended implantation site.
- a small slit distanced away from the implantation site for example a 1-2 mm slit about 5-15 mm away from the implantation site, reduces the possibility of aqueous humor flowing out of the conjunctiva through the slit, reduces the possibility of infection, reduces the possibility of scarring over the axial outlet of the implant, and facilitates closing and healing.
- the implant 30 by delivery device 60 , is passed through the slit 26 , under the conjunctiva 18 , to the implantation site in the sclera 14 .
- FIG. 9 shows the advancement of the implant only schematically; it will be appreciated that in practice the implant is directed from the slit to the implantation site generally along the surface of the sclera, such that the longitudinal axis of the implant is generally parallel to the surface of the sclera.
- the implant Upon reaching the implantation site, the implant is tilted for penetration into the sclera
- the acute angle of the needle-like tip formed by the beveled surface 36 of the implant 30 ensures that the implant 30 enters the sclera 14 easily.
- the needle-like tip penetrates through the sclera 14 into the anterior chamber 20 of the eyeball 10 , while the flanged disk 34 is pushed up against the sclera 14 .
- the retention spur (or spurs) 52 anchors the implant 30 in the eyeball 10 and prevents the implant 30 from sliding out as the delivery device 60 is withdrawn.
- the retention spur 52 also prevents the implant 30 from slipping out once in place.
- the delivery device may comprise an ‘internal’ or ‘external’ needle.
- a straight or twisted guide wire known in the art, may also be used to guide the delivery device to its precise position.
- the delivery device may be vibrated, or a lubricant, such as medical paste or gel, can be spread onto the delivery device.
- a suitable fibrosis inhibiting compound e.g. 5FU, mitomycin
- FIG. 11 shows an alternative embodiment of an intraocular implant 130 constructed in accordance with the invention.
- the implant 130 comprises a tube 132 attached to an elliptical flanged disk 134 .
- the tube 132 has an inlet end 140 , an outlet end 150 , and a tube passage 138 , with the tube passage 138 having an axial inlet 141 , an axial outlet 151 , and circumferential holes 142 to drain the aqueous humor from the anterior chamber 20 of the eyeball 10 into the space under the conjunctiva 18 .
- the distal end 152 of the tube 132 has a partially conical shape.
- a plurality of retention projections in the form of retention flanges 158 are formed on the outer circumference of the tube 132 , approximately parallel to the flanged disk 134 , to act as anchors to retain the implant 130 in the eyeball.
- the flanged disk 134 comprises an elliptical base 144 , an outer rim 146 , and an inner upright curved to form an inner rim 148 , defining therebetween a reservoir 154 .
- a plurality of “U”-shaped passageways 156 are formed in the inner rim 148 for allowing aqueous humor to flow from the axial outlet 151 into the reservoir 154 .
- the outer rim 146 and the inner rim 148 prevent the conjunctiva 18 from clogging the axial outlet 151 .
- the flanged disk 134 is elliptical in shape.
- the longer axis of the flanged disk 134 is approximately twice the diameter of the tube 132 , and the flanged disk 134 is eccentrically displaced relative to the tube 132 .
- the elliptical shape and placement of the flanged disk 134 allows a wide anchoring area for the implant 130 and maximizes the outlet drainage area on the longer axis of the ellipse.
- the shorter axis of the ellipse enables the implant 130 to fit within the narrow space under the conjunctiva 18 .
- FIG. 13 illustrates a delivery device 160 and a method of inserting the intraocular implant 130 into an eyeball.
- the implant 130 is slidably fixed over a needle 164 of the delivery device 160 , which, similar to a standard medical syringe, has needle 164 attached to a housing 162 .
- the tip 174 of needle 164 which passes through the implant 130 , is acutely angled so that the tip 174 is generally in line with the angle of the lower part the implant 130 .
- a front surface of the delivery device 160 is formed as an abutment surface angled to match the angle of the flanged disk 134 and further comprises an indent 172 to hold the implant 130 in place during implantation.
- the shape of the delivery device 160 and the angled surface of the flanged disk 134 prevent the implant 130 from rotating during implantation.
- the delivery device 160 shown in FIG. 13 is used in a manner similar to that described above with reference to FIGS. 8 through 10. In this embodiment, however, the acute angle of the needle tip 174 pierces the sclera. The angled inlet end of the implant device 130 follows the needle tip 174 through the sclera 14 , into the anterior chamber 20 of the eyeball. As shown in FIG. 14, the retention flanges 158 anchor the implant 130 in position and prevent the implant 130 from sliding out as the delivery device 160 is withdrawn. The anchorage of the retention flanges 158 also prevents the implant 130 from slipping out once in place
- FIGS. 15 and 16 illustrate a third embodiment of an intraocular implant according to the invention. This embodiment is similar to that shown in FIGS. 1 through 10, with the exception that a separately attached retention projection in the form of a retention plate 252 is used for anchoring instead of the retention spur 52 .
- the retention plate is inserted into a groove 253 in the tube of the implant 230 and may be fastened by any suitable means, for example by welding in the case of an implant 230 constructed of stainless steel.
- An intraocular implant constructed in accordance with the invention may be manufactured entirely from or covered with any suitable material such as stainless steel, silicon, gold, nitinol, Teflon, tantalum, PMMA, or any other suitable plastic or other material.
- the implant may also be coated with heparin or any other suitable biology active compound.
- Manufacture of an intraocular implant in accordance with the invention may be carried out according to the following process.
- the tube may be formed from the tip of a standard stainless steel hypodermic needle.
- small holes are drilled proximate the tip of the needle to form the circumferential holes.
- the needle is cut at the appropriate angle to correspond to the desired angle of the flanged disk
- the side of the needle is then undercut to form a projection which can be later bent outwardly to form the sour.
- the disk may be chemically etched from a stainless steel sheet according to the following process.
- a pattern of the disk is drawn on a computer aided design (CAD) system and plotted on a transparent film using a laser plotter. Plottings are made of both the upper side and the lower side of the disk.
- the plotting for the upper side for example, includes the outer rim and the inner uprights; the plotting for the lower side, for example, includes the base of the disk.
- a layer of photoresist is adhered to both surfaces of the stainless steel sheet.
- the photoresist is then exposed to UV light through the film on which the plottings are made. The areas of the sheet which are blocked by the plottings are not exposed.
- the photoresist which has been exposed to UV light is then chemically removed.
- the stainless steel sheet is then etched, so that the chemical eats away the areas of the sheet from which the photoresist has been removed.
- the etching is time-controlled such that the chemical only takes away material to a predetermined depth.
- the chemical on the upper surface of the sheet takes away material on the outside of the disk, in the reservoir including between the uprights, and in the center of the disk which is to receive the tube. Because the etching is time-controlled, the chemical acting on the top of the sheet takes away material only part way through the thickness of the sheet.
- the chemical on the lower surface of the sheet takes away material on the outside of the disk and in the center of the disk which is to receive the tube. The chemical acting on the bottom of the sheet takes away material part way through the thickness of the sheet.
- the material on the outside of the disk and in the center of the disk which is to receive the tube is completely taken away by the etching process through the entire thickness of the sheet.
- a small projection may be left on the outside of the disk during the etching process to prevent the disk from being dislodged from the sheet.
- an implant made of plastic may be manufactured by a suitable molding operation.
Abstract
An ophthalmic implant for treatment of glaucoma, a delivery device for implanting such an implant, and a method of implanting such an implant. The implant includes a tube having an inlet end, an outlet end, and a tube passage therebetween, and a disk connected to the tube at the outlet end of the tube. The tube passage has a cross-sectional area sufficiently small to inhibit the flow of aqueous humor through the tube passage. The implant provides a bleb of aqueous humor under the conjunctiva so that the bleb and the elasticity of the conjunctiva assist in regulating the flow of aqueous humor through the tube as a function of the IOP. The tube at its inlet end has a beveled surface facing away from the iris and one or more circumferential holes. One or more retention projections are provided for anchoring and may be extended outwardly when the implant is implanted in the eyeball. The disk has an outer rim and one or more inner uprights. The implant is implanted by use of a delivery device comprising a handle and a rodlike instrument, with a tip for insertion into the tube passage of the implant and a retention mechanism for retaining the implant. During implantation, the implant is inserted through a slit in a portion of the conjunctiva which normally lies at a distance away from the intended implantation site.
Description
- The invention relates generally to ophthalmic implants for treatment of glaucoma, delivery devices for implanting such implants, and to methods of implanting such implants.
- Glaucoma is an eye condition characterized by an increase in the intraocular pressure (IOP) of the eye to an abnormal level. A normal eye maintains a proper IOP by the circulation within the eye of aqueous humor aqueous humor is secreted from the ciliary body, passes through the pupil into the anterior chamber of the eyeball, and is filtered out of the eyeball via the trabeculum and the Canal of Schlemm. With glaucoma, the aqueous humor excretory pathway is blocked, the aqueous humor cannot pass out of the eyeball at an adequate rate, the IOP rises, the eyeball becomes harder, and the optic nerve atrophies by the pressure applied on its fibers leaving the retina. A characteristic optic neuropathy develops, resulting in progressive death of the ganglion cells in the retina, restriction of the visual field, and eventual blindness. Advanced stages of the disease are characterized also by significant pain.
- Glaucoma treatment, it initiated early in the course of the disease, can prevent further deterioration and preserve most of the ocular functions. The goal of glaucoma treatment is to reduce the IOP to level which is considered safe for a particular eye, but which is not so low as to cause ocular malfunction or retinal complications.
- One type of glaucoma treatment is filtration surgery, which provides an alternate route for aqueous humor to exit the anterior chamber of the eyeball and enter the sub-conjunctival space, thereby lowering the IOP. In full thickness operations a fistula is created through the limbal sclera, connecting directly the anterior chamber of the eyeball and the sub-conjunctival space. Full thickness operations provide long-lasting control of IOP; however, excessive loss of aqueous humor from the eyeball during the early postoperative period frequently leads to hypotony.
- In guarded filtration surgery (trabeculectomy), a fistula created through the limbal sclera is protected by an overlying partial thickness sutured scleral flap. The scleral flap provides additional resistance to excessive loss of aqueous humor from the eyeball, thereby reducing the risk of early postoperative hypotony. However, trabeculectomy may result in higher eventual IOP and increased risk of late failure of filtration, compared with full thickness operations.
- In accordance with one recently introduced procedure, a full thickness filtering fistula may be created by a holmium laser probe, with minimal surgically induced trauma. After retrobulbar anesthesia, a conjunctival incision (approximately 1 mm) is made about 12-15 mm posterior to the intended sclerostomy site, and a laser probe is advanced through the sub-conjunctival space to the limbus. Then, multiple laser pulses are applied until a full thickness fistula is created. This technique has sometimes resulted in early hypocony on account of a difficulty in controlling the sclerostomy size. In addition, early and late iris prolapse into the sclerostomy has resulted in abrupt closure of the fistula and eventual surgical failure. Further, despite its relative simplicity, the technique still necessitates the use of retrobulbar anesthesia to avoid pain caused by the laser applications. The injection of anesthetic material close to the already damaged optic nerve may sometimes lead to further visual damage. A further disadvantage of this procedure, as well as other types of glaucoma filtration surgery, is the propensity of the fistula to be sealed by scarring.
- Various attempts have been made to overcome the problems of filtration surgery, for example, by using ophthalmic implant devices. Typical ophthalmic implants utilize drainage tubes so as to maintain the integrity of the openings formed in the eyeball for the relief of the IOP.
- Typical ophthalmic implants suffer from several disadvantages. For example, the implants typically utilize a valve mechanism for regulating the flow of aqueous humor from the eyeball; defects in and/or failure of such valve mechanisms could lead to excessive loss of aqueous humor from the eyeball and possible hypotony. The implants also tend to clog over time, either from the inside by tissue, such as the iris, being sucked into the inlet, or from the outside by the proliferation of cells, for example by scarring. Additionally, the typical implant insertion operation is complicated, costly and takes a long time.
- U.S. Pat. No. 3,788,327 to Donowitz et al. shows a prior art implant utilizing a valve mechanism for regulating the flow of aqueous humor from the eyeball. As stated above, defects in and/or failure of such a valve mechanism could lead to excessive loss of aqueous humor from the eyeball and possible hypotony. Additionally, both the inlet opening and the outlet opening in the implant shown in U.S. Pat. No. 3,788,327 may be susceptible to clogging—the inlet opening by the iris and the outlet opening by scarring. Finally, implantation of an implant according to U.S. Pat. No. 3,788,327 may involve the separate steps of first providing a tract for receiving the implant and/or suturing the implant once it is in place, which add time and possible complications to the operation.
- It is an object of the invention to provide an improved ophthalmic implant which may be implanted into the eyeball for the treatment of glaucoma, a delivery device for implanting such an implant, and an improved method of implanting such an implant into the eyeball.
- In one embodiment of an improved implant in accordance with the invention, an intraocular implant is provided to be implanted in the eyeball. The implant includes a tube having an inlet end, an outlet end, and a tube passage therebetween for permitting aqueous humor to flow out of the eyeball, and a flanged disk connected to the tube at the outlet end of the cube. The cube passage has a cross-sectional area sufficiently small to inhibit the flow of aqueous humor through the tube passage when the IOP is below a threshold amount, thereby preventing the IOP from falling below its critical limit.
- The flanged disk, which is designed to be located underneath the conjunctiva, may have an outer rim for forming a reservoir having an enlarged cross-sectional area relative to the cross-sectional area of the tube passage. When the IOP is above the threshold amount such that aqueous humor is able to flow through the tube passage, the elasticity of the conjunctiva in conjunction with this design of the flanged disk assists in regulating the flow of aqueous humor through the tube as a function of the IOP.
- To prevent clogging of the implant, the tube at its inlet end may be provided with a beveled surface which faces away from the iris when the implant is inserted. Additionally, one or more circumferential holes may be provided along the tube for allowing aqueous humor to flow into the tube passage even if the axial inlet opening is blocked.
- To prevent clogging at the outlet end, the flanged disk may have an outer rim as described above which raises the conjunctiva away from the axial outlet of the tube passage to allow outflow. One or more inner uprights (which may be in the form of an inner rim) may also be provided on the flanged disk for this purpose. Clogging is further avoided by implanting the implant under the conjunctiva at a distance away from an insertion slit in the conjunctiva, such that healing of the slit does not cause scar tissue to form in the area of the axial outlet opening of the implant.
- Implantation may be facilitated by further features of the implant. For example, the implant may have one or more retention projections (for example, in the form of a spur, flange, or plate). The retention projection may be rigid, or it may be made of an elastic material such that it is able to be flexed inward against the tube during penetration through the sclera. Alternatively, the retention projection may be designed to lie initially relatively flat against the tube for easier penetration through the sclera and to prevent tearing of the sclera, with a mechanism for extending the retention projection outwardly when the implant is implanted in the eyeball. For example, the retention projection may be extended outwardly by a separate expansion tool or may be constructed of a shape memory alloy so that it is extended outwardly when subjected to the heat of the eyeball. One or more retention projections according to the invention are sufficient to reliably anchor the implant in the eyeball without the need for sutures, saving time and costs.
- Implantation may also be facilitated by the provision of one or more markers on the implant visible through the cornea upon passing through the sclera. For example, a circumferential hole as described above may serve as a marker; alternatively, the marker may be some other suitable visible mechanism, such as a scratch or colored mark on the cube. The visibility of the marker lets the doctor know that the marker has passed through the sclera, indicating that the implant is in place.
- Implantation of an implant may be performed by use of a delivery device in accordance with the invention, comprising a handle and a rodlike instrument, for example a needle or probe, for carrying the implant for insertion into the eyeball. The delivery device has a tip for insertion into the tube passage of the implant and a suitable retention mechanism for preventing the implant from moving up the delivery device during implantation. The retention mechanism may also be constructed to prevent the implant from rotating during implantation to insure proper orientation of the implant in the eyeball. The delivery device may additionally have a suitable expansion tool for extending one or more retention projections of the implant outwardly once the projection or projections have penetrated through the sclera.
- In one embodiment of an improved method of implanting an implant according to the invention, a small slit is cut in a portion of the conjunctiva which normally lies at a distance away from the intended implantation site. As the implant itself is very small, the slit also may be very small, for example about 2 mm in length or less. The small size of the slit as well as its positioning at a distance away from the implantation site, for example about 10 mm, helps prevent contamination of the sclerostomy site and reduces the risk of infection.
- The implant is placed through the slit, directed to the implantation site, and inserted into the sclera at the implantation site. The sclera may be pierced either by a needle-like tip of the tube of the implant formed by a beveled surface at the inlet end of the tube as described above or by the tip of a needle of the delivery device which carries the implant. Thus, the implant may be inserted directly into the eyeball without the need for any separate piercing step, resulting in cost and time savings.
- An intraocular implant, delivery device, and method of implantation according to the invention provide the advantages of a full thickness fistula, while avoiding the limitations of the standard trabeculectomy. An implant according to the invention may be very small and implantable without surgery. No surgery room or hospitalization is necessary, thereby reducing costs. Implantation is minimally invasive, simple and quick, requiring only local anesthesia. Retrobulbar anaesthesia is not necessary, and thus iatrogenic damage to the optic nerve is avoided There is no need to perform an iridectomy, and thus aqueous flow is maintained, lens nourishment is unaffected, and the likelihood of cataracts developing as a result of the procedure is reduced.
- FIG. 1 is a schematic cross-sectional view of a first embodiment of an intraocular implant according to the invention, shown inserted in an eyeball;
- FIG. 2 is an enlarged perspective view of the intraocular implant of FIG. 1;
- FIG. 3 is a view similar to FIG. 2, with part of the intraocular implant cut away to show a sectional view thereof;
- FIG. 4 is an enlarged perspective view of a disk portion of the intraocular implant of FIG. 1;
- FIGS. 5 through 7 illustrate the action of the conjunctiva during operation of the incraocular implant of FIG. 1;
- FIGS. 8 through 10 illustrate a delivery device and insertion of the intraocular implant of FIG. 1 into an eyeball;
- FIG. 11 is an enlarged perspective view of a second embodiment of an intraocular implant according to the invention, with part of the intraocular implant cut away to show a sectional view thereof;
- FIG. 12 is a cop view of the incraocular implant of FIG. 11, showing a flanged disk portion of the implant;
- FIG. 13 illustrates a delivery device and insertion of the intraocular implant of FIG. 11 into an eyeball;
- FIG. 14 is a schematic cross-sectional view of the intraocular implant of FIG. 11, shown inserted in an eyeball; and
- FIGS. 15 and 16 illustrate a third embodiment of an intraocular implant according to the invention.
- FIG. 1 illustrates an
intraocular implant 30, constructed in accordance with an embodiment of the invention, implanted in aneyeball 10. Theimplant 30 comprises a needle-like tube 32 and aflanged disk 34. The plane of theflanged disk 34 forms an angle with thetube 32 chat corresponds to the angle between the surface of thesclera 12 and the axis of insertion of theimplant 30. Theimplant 30 is inserted in thesclera 12 of theeyeball 10, in thelimbal area 14 adjacent to thecornea 16, and protrudes into theanterior chamber 20 adjacent theiris 22. Theimplant 30 is inserted so that theflanged disk 34 is placed on a surface of thesclera 12 underneath theconjunctiva 18. Theimplant 30 may be placed above or below the Tenon's capsule (not shown) It will be appreciated by persons of ordinary skill in the art that the exact location for inserting theimplant 30 is not restricted to that shown, and may be any other suitable position, such as behind theiris 22. - FIG. 2 shows an enlarged perspective view of the
implant 30 of FIG. 1, and FIG. 3 shows a similar view, with part of theimplant 30 cut away. Thetube 32, which may take the form of a modified standard retrobulbar tip, has aninlet end 40, anoutlet end 50, and atube passage 38 extending therebetween, with thetube passage 38 having anaxial inlet 41 and anaxial outlet 51. Theflanged disk 34 is connected to thetube 32 at itsoutlet end 50. The entire implant is very small; for example thecube 32 may have a length of about 2 mm and a width of about 0.5 mm, and theflanged disk 34 may have a diameter of about 1 mm and a thickness of less that 0.1 mm. - The
tube passage 38 has a cross-sectional area sufficiently small to inhibit the flow of aqueous humor through the cube passage when the IOP of the eye is below a threshold amount, thereby preventing the IOP from falling below its critical limit. In one embodiment, for example, thecylindrical tube passage 38 has a diameter of 300 micrometers, such that an IOP of 5 mm Hg is needed for the aqueous humor to flow out. Thus, by using a specified internal cross-sectional area for the tube passage, excessive loss of aqueous humor from the eyeball is prevented. - When the IOP is above the threshold amount, aqueous humor drains from the
anterior chamber 20 of theeyeball 10 through theaxial inlet 41 and one or more circumferential holes 72, through thetube passage 38, and into the space under theconjunctiva 18. The circumferential holes 42 may take any suitable form; for example, they may be in the form of circular openings whose combined cross-sectional area is equal to the cross-sectional area of thetube passage 38. The circumferential holes 42 prevent thetube passage 38 from becoming clogged at its inlet end because, even if theiris 22 obstructs theaxial inlet 41, aqueous humor can still pass through the circumferential holes 42. In the event theaxial inlet 41 is obstructed, thecircumferential holes 42 also serve to cause a back pressure in thetube passage 38 to unclog theaxial inlet 41. The circumferential holes 42 serve the additional purpose of insuring a proper insertion depth of theimplant 30, as the upper hole is visible during implantation after penetration through the sclera and thus can be used as a marker. To serve this function, any other suitable marker (such as a scratch or colored mark) may be used. - The
inlet end 40 of thetube 32 has a needle-like tip formed by abeveled surface 36, angled sharply for easy insertion into the eyeball. Thebeveled surface 36 increases the area of theaxial inlet 41 to enlarge the entrance to thetube passage 38. Thebeveled surface 36 is designed to face away from theiris 22 to reduce the possibility of obstruction of theaxial inlet 41. Because theflanged disk 34 is designed to rest against thesclera 14 and thebeveled surface 36 is designed to face away from theiris 22, the beveled-surface 36 lies in a plane which is angled opposite to the plane in which theflanged disk 34 lies. - The
tube 32 may have one or more retention projections in the form of one ormore spurs 52 provided integrally with it for retaining theimplant 30 in theeyeball 10 after insertion. Alternatively, the retention spur 52 may be made as a separate part connected to thetube 32 by, for example, welding or brazing. The retention spur 52 may be rigid, or it may be flexible such chat it bends coward thetube 32 during penetration of the sclera and springs outward to its original shape after passing through the sclera. Alternatively, the retention sour 52 may be designed for plastic deformation by a separate expansion tool (for example, a balloon) once it is in theeyeball 10, or the retention spur 52 may be constructed of a shape memory alloy such that the spur is flat against the tube when cool but expands to its final shape when subjected to the heat of theeyeball 10. - The
flanged disk 34, shown enlarged in FIG. 4, comprises abase 44, anouter rim 46, and a plurality ofinner uprights 48. Thebase 44 andouter rim 46 define areservoir 54 such that, in operation, the aqueous humor flows out of theaxial outlet 51 of thetube passage 38, between theuprights 48, and into thereservoir 54. The enlarged cross-sectional area of thereservoir 54 as compared to the cross-sectional area of thetube passage 38 provides a larger area for absorption of the aqueous humor by theconjunctiva 18 and also acts in conjunction with the elasticity of theconjunctiva 18 to assist in regulating the flow of aqueous humor through theimplant 30 as a function of the IOP. - FIGS. 5 through 7 illustrate the action of the
conjunctiva 18 during operation of theimplant 30, in which it can be seen that the aqueous humor which flows out of the tube passage forms a “bleb” 24 below theconjunctiva 18. It will be appreciated by persons having ordinary skill in the art that a higher IOP results in a higher flow rate through theimplant 30, and a greater force of the aqueous humor on theconjunctiva 18. - In addition to defining the
reservoir 54, theouter rim 46 of theflanged disk 34 serves the additional purpose of raising theconjunctiva 18 away from theaxial outlet 51 to prevent clogging of thetube passage 38. Theinner uprights 48 also serve this purpose. - The shape of the
flanged disk 34 may be, but is not limited to, an ellipse, and it will be appreciated by persons having ordinary skill in the art that it may conform to any shape which allows the implant to fit under theconjunctiva 18 and which regulates the IOP. The size and/or shape of theflanged disk 34 and/or the angle between theflanged disk 34 and thetube 32 can also be changed in order to use different implants for different persons' eyes. - FIGS. 8 through 10 illustrate a
delivery device 60 and a method of inserting theintraocular implant 30 into an eyeball. Theimplant 30 is first attached to thedelivery device 60, having ahandle 62 and a suitablerodlike instrument 64 such as a needle or probe. Therodlike instrument 64 has atip 70 for penetrating a tube passage of theimplant 30 and a retention mechanism for preventing the implant from moving up the delivery device during implantation, for example in the form of anabutment surface 68 having an angle generally corresponding to that of theflanged disk 34. This configuration also prevents rotation of theimplant 30 on thedelivery device 60, thereby insuring proper orientation of the implant in the eyeball. The retention mechanism may also include one or more projections for extending inside the outer rim and/or between the inner uprights on theflanged disk 34. In an alternative embodiment, the retention mechanism may be the tip of the rodlike instrument, constructed to engage the inside of the tube passage of the implant with a friction fit, thereby preventing the implant from moving up the delivery device during implantation. - A
delivery device 60 in which the rodlike instrument is aneedle 65 is illustrated in FIG. 9. In that illustrated embodiment, thedelivery device 60 is similar to a standard medical syringe having a housing and aneedle 65 with abore 67. Thefront tip 69 of theneedle 65 is configured as an abutment surface having an angle generally corresponding to that of theflanged disk 34. Thebore 67 of theneedle 65 has a tip in the form of aplug 71 which is configured to have a cross-sectional shape corresponding to that of thetube passage 38. Theimplant 30 is placed over theplug 71, with the end of theplug 71 projecting into thetube passage 38, and with thefront tip 69 of theneedle 65 abutting against theflanged disk 34. Theplug 71 blocks thetube passage 38 during implantation. - To insert the
implant 30 into theeyeball 10, asmall slit 26 is cut in a portion of theconjunctiva 18 which normally lies at a distance away from aportion 28 of theconjunctiva 18 which normally covers the intended implantation site. A small slit distanced away from the implantation site, for example a 1-2 mm slit about 5-15 mm away from the implantation site, reduces the possibility of aqueous humor flowing out of the conjunctiva through the slit, reduces the possibility of infection, reduces the possibility of scarring over the axial outlet of the implant, and facilitates closing and healing. - The
implant 30, bydelivery device 60, is passed through theslit 26, under theconjunctiva 18, to the implantation site in thesclera 14. FIG. 9 shows the advancement of the implant only schematically; it will be appreciated that in practice the implant is directed from the slit to the implantation site generally along the surface of the sclera, such that the longitudinal axis of the implant is generally parallel to the surface of the sclera. Upon reaching the implantation site, the implant is tilted for penetration into the sclera The acute angle of the needle-like tip formed by thebeveled surface 36 of theimplant 30 ensures that theimplant 30 enters the sclera 14 easily. The needle-like tip penetrates through the sclera 14 into theanterior chamber 20 of theeyeball 10, while theflanged disk 34 is pushed up against thesclera 14. - When the
implant 30 is in place, as shown in FIG. 10, the retention spur (or spurs) 52 anchors theimplant 30 in theeyeball 10 and prevents theimplant 30 from sliding out as thedelivery device 60 is withdrawn. The retention spur 52 also prevents theimplant 30 from slipping out once in place. - It will be appreciated by persons having ordinary skill in the art that the insertion of the implant is not restricted to the method described above, and it may be inserted by any of several methods known in the art. The delivery device may comprise an ‘internal’ or ‘external’ needle. A straight or twisted guide wire, known in the art, may also be used to guide the delivery device to its precise position. To ease insertion, the delivery device may be vibrated, or a lubricant, such as medical paste or gel, can be spread onto the delivery device. Additionally, after implantation of the implant a suitable fibrosis inhibiting compound (e.g. 5FU, mitomycin) may be applied to the implantation site.
- FIG. 11 shows an alternative embodiment of an
intraocular implant 130 constructed in accordance with the invention. Theimplant 130 comprises atube 132 attached to an ellipticalflanged disk 134. Thetube 132 has aninlet end 140, anoutlet end 150, and atube passage 138, with thetube passage 138 having anaxial inlet 141, anaxial outlet 151, andcircumferential holes 142 to drain the aqueous humor from theanterior chamber 20 of theeyeball 10 into the space under theconjunctiva 18. - The
distal end 152 of thetube 132 has a partially conical shape. A plurality of retention projections in the form ofretention flanges 158 are formed on the outer circumference of thetube 132, approximately parallel to theflanged disk 134, to act as anchors to retain theimplant 130 in the eyeball. - As shown in the enlarged view in FIG. 12, the
flanged disk 134 comprises anelliptical base 144, anouter rim 146, and an inner upright curved to form aninner rim 148, defining therebetween areservoir 154. A plurality of “U”-shapedpassageways 156 are formed in theinner rim 148 for allowing aqueous humor to flow from theaxial outlet 151 into thereservoir 154. Theouter rim 146 and theinner rim 148 prevent theconjunctiva 18 from clogging theaxial outlet 151. - As shown in FIG. 12, the
flanged disk 134 is elliptical in shape. The longer axis of theflanged disk 134 is approximately twice the diameter of thetube 132, and theflanged disk 134 is eccentrically displaced relative to thetube 132. The elliptical shape and placement of theflanged disk 134 allows a wide anchoring area for theimplant 130 and maximizes the outlet drainage area on the longer axis of the ellipse. The shorter axis of the ellipse enables theimplant 130 to fit within the narrow space under theconjunctiva 18. - FIG. 13 illustrates a
delivery device 160 and a method of inserting theintraocular implant 130 into an eyeball. Theimplant 130 is slidably fixed over aneedle 164 of thedelivery device 160, which, similar to a standard medical syringe, hasneedle 164 attached to ahousing 162. Thetip 174 ofneedle 164, which passes through theimplant 130, is acutely angled so that thetip 174 is generally in line with the angle of the lower part theimplant 130. - A front surface of the
delivery device 160 is formed as an abutment surface angled to match the angle of theflanged disk 134 and further comprises anindent 172 to hold theimplant 130 in place during implantation. The shape of thedelivery device 160 and the angled surface of theflanged disk 134 prevent theimplant 130 from rotating during implantation. - The
delivery device 160 shown in FIG. 13 is used in a manner similar to that described above with reference to FIGS. 8 through 10. In this embodiment, however, the acute angle of theneedle tip 174 pierces the sclera. The angled inlet end of theimplant device 130 follows theneedle tip 174 through thesclera 14, into theanterior chamber 20 of the eyeball. As shown in FIG. 14, theretention flanges 158 anchor theimplant 130 in position and prevent theimplant 130 from sliding out as thedelivery device 160 is withdrawn. The anchorage of theretention flanges 158 also prevents theimplant 130 from slipping out once in place - FIGS. 15 and 16 illustrate a third embodiment of an intraocular implant according to the invention. This embodiment is similar to that shown in FIGS. 1 through 10, with the exception that a separately attached retention projection in the form of a
retention plate 252 is used for anchoring instead of theretention spur 52. The retention plate is inserted into agroove 253 in the tube of theimplant 230 and may be fastened by any suitable means, for example by welding in the case of animplant 230 constructed of stainless steel. - An intraocular implant constructed in accordance with the invention may be manufactured entirely from or covered with any suitable material such as stainless steel, silicon, gold, nitinol, Teflon, tantalum, PMMA, or any other suitable plastic or other material. The implant may also be coated with heparin or any other suitable biology active compound.
- Manufacture of an intraocular implant in accordance with the invention may be carried out according to the following process. The tube may be formed from the tip of a standard stainless steel hypodermic needle. Using an EDM machine, small holes are drilled proximate the tip of the needle to form the circumferential holes. At a distance from the tip corresponding to the desired length of the tube, the needle is cut at the appropriate angle to correspond to the desired angle of the flanged disk The side of the needle is then undercut to form a projection which can be later bent outwardly to form the sour.
- The disk may be chemically etched from a stainless steel sheet according to the following process. A pattern of the disk is drawn on a computer aided design (CAD) system and plotted on a transparent film using a laser plotter. Plottings are made of both the upper side and the lower side of the disk. The plotting for the upper side, for example, includes the outer rim and the inner uprights; the plotting for the lower side, for example, includes the base of the disk.
- A layer of photoresist is adhered to both surfaces of the stainless steel sheet. The photoresist is then exposed to UV light through the film on which the plottings are made. The areas of the sheet which are blocked by the plottings are not exposed. The photoresist which has been exposed to UV light is then chemically removed.
- Using an etching chemical, the stainless steel sheet is then etched, so that the chemical eats away the areas of the sheet from which the photoresist has been removed. The etching is time-controlled such that the chemical only takes away material to a predetermined depth.
- By use of a plotting for the upper side which includes the outer rim and the uprights, the chemical on the upper surface of the sheet takes away material on the outside of the disk, in the reservoir including between the uprights, and in the center of the disk which is to receive the tube. Because the etching is time-controlled, the chemical acting on the top of the sheet takes away material only part way through the thickness of the sheet. By use of a plotting for the lower side which includes the base of the disk, the chemical on the lower surface of the sheet takes away material on the outside of the disk and in the center of the disk which is to receive the tube. The chemical acting on the bottom of the sheet takes away material part way through the thickness of the sheet. Because of action from both the top and the bottom, the material on the outside of the disk and in the center of the disk which is to receive the tube is completely taken away by the etching process through the entire thickness of the sheet. A small projection may be left on the outside of the disk during the etching process to prevent the disk from being dislodged from the sheet.
- It will be appreciated by persons having ordinary skill in the art that variations on this manufacturing process and other manufacturing processes are possible. For example, an implant made of plastic may be manufactured by a suitable molding operation.
- As will also be appreciated by persons having ordinary skill in the art, the various embodiments of intraocular implants, delivery devices, and methods for implantation described hereinabove are given by way of example only. Various changes, modifications and variations may be applied to the described embodiments without departing from the scope of the invention, defined by the appended claims.
Claims (31)
1. An intraocular implant for implantation in an eyeball comprising:
a tube for implanting into the eyeball comprising an inlet end, an outlet end, and a tube passage extending between the inlet end and the outlet end for permitting aqueous humor to flow out of the eyeball; and
a flanged disk connected to the tube at the outlet end of the tube for placing on a surface of the eyeball;
wherein the tube passage has a cross-sectional area sufficiently small to inhibit the flow of aqueous humor through the tube passage when an intraocular pressure of the eyeball is below a threshold amount.
2. An intraocular implant according to claim 1 wherein the tube passage is cylindrical, and wherein a diameter of the tube passage is substantially smaller than a length of the tube passage.
3. An intraocular implant according to claim 2 wherein the diameter of the tube passage is about 300 micrometers or less.
4. An intraocular implant for implantation in an eyeball comprising:
a tube for implanting into the eyeball comprising an inlet end with a beveled surface at the inlet end, an outlet end, and a tube passage extending between the inlet end and the outlet end for permitting aqueous humor to flow out of the eyeball; and
a flanged disk connected to the tube at the outlet end of the tube for placing on a surface of the eyeball;
wherein the beveled surface at the inlet end of the tube lies in a first plane forming an angle with the longitudinal axis of the tube and the flanged disk lies in a second plane which is angled opposite to the first plane.
5. An intraocular implant for implantation in an eyeball comprising:
a tube for implanting into the eyeball comprising an inlet end, an outlet end, and a tube passage extending between the inlet end and the outlet end for permitting aqueous humor to flow out of the eyeball; and
a flanged disk connected to the tube at the outlet end of the tube for placing on a surface of the eyeball;
wherein the tube has at least one circumferential hole which opens into the tube passage proximate the inlet end of the tube.
6. An intraocular implant for implantation in an eyeball comprising:
a tube for implanting into the eyeball comprising an inlet end, an outlet end, and a tube passage extending between the inlet end and the outlet end for permitting aqueous humor to flow out of the eyeball; and
a flanged disk connected to the tube at the outlet end of the tube for placing on a surface of the eyeball;
wherein the flanged disk comprises a base, an outer rim, and at least one inner upright, and wherein the base and outer rim form a reservoir having a larger cross-sectional area than the tube passage.
7. An intraocular implant according to claim 6 wherein at least one inner upright is curved to form an inner rim proximate an axial outlet opening of the tube and substantially bounding the axial outlet opening of the tube, the flanged disk further comprising at least one passageway in the inner rim for enabling flow of aqueous humor from the axial outlet opening through the passageway.
8. An intraocular implant according to claim 6 wherein the flanged disk has an elliptical shape.
9. An intraocular implant for implantation in an eyeball comprising:
a tube for implanting into the eyeball comprising an inlet end, an outlet end, and a tube passage extending between the inlet end and the outlet end for permitting aqueous humor to flow out of the eyeball; and
a flanged disk connected to the tube at the outlet end of the tube for placing on a surface of the eyeball;
wherein the implant has at least one retention projection for anchoring the implant in the eyeball, said retention projection being extended outwardly when the implant is implanted in the eyeball.
10. An intraocular implant according to claim 9 wherein at least one retention projection is extended outwardly by an expansion tool when the implant is implanted in the eyeball.
11. An intraocular implant according to claim 9 wherein at least one retention projection is constructed of a shape memory alloy and is extended outwardly when subjected to the heat of the eyeball when the implant is implanted in the eyeball.
12. A method of regulating an intraocular pressure of an eyeball comprising the steps of:
providing an intraocular implant comprising (a) a tube for implanting into the eyeball, said tube comprising an inlet end, an outlet end, and a tube passage extending between the inlet end and the outlet end for permitting aqueous humor to flow out of the eyeball, said tube passage having a cross-sectional area sufficiently small to inhibit the flow of aqueous humor through the tube passage when an intraocular pressure of the eyeball is below a threshold amount, and (b) a flanged disk connected to the tube at the outlet end of the tube for placing on a surface of the eyeball; and
implanting the intraocular implant in the eyeball including implanting the tube into the eyeball and placing the flanged disk on a surface of the eyeball.
13. A delivery device for implanting an intraocular implant into an eyeball, the delivery device comprising:
a handle; and
a rodlike instrument;
wherein the rodlike instrument comprises a tip for penetrating a tube passage of the implant and a retention mechanism for retaining the implant on the delivery device.
14. A delivery device according to claim 13 wherein the rodlike instrument comprises a probe.
15. A delivery device according to claim 13 wherein the rodlike instrument comprises a needle.
16. A delivery device according to claim 15 wherein the tip of the rodlike instrument for penetrating a cube passage of the implant comprises a plug inserted in a bore of the needle.
17. A delivery device according to claim 13 wherein the retention mechanism comprises an abutment surface for abutting a flanged disk of the implant, wherein the abutment surface has an angle generally corresponding to an angle of the flanged disk.
18. A method of implanting an intraocular implant into an eyeball comprising the steps of:
attaching the implant to a delivery device;
cutting a slit in a portion of the conjunctiva of the eyeball which normally lies at a distance away from an intended implantation site;
placing the implant by the delivery device through the slit in the conjunctiva;
directing the implant by the delivery device to the implantation site;
inserting the implant through the sclera at the implantation site;
withdrawing the delivery device; and
allowing the slit in the conjunctiva to be lie at the distance away from the implantation size.
19. A method of implanting an intraocular implant according to claim 18 wherein the distance between the slit in the conjunctiva and the implantation site is about 5 millimeters or more.
20. A method of implanting an intraocular implant according to claim 18 wherein the slit has a length of about 2 millimeters or less.
21. A method of implanting an intraocular implant according to claim 18 wherein, in the step of inserting the implant through the sclera, the sclera is penetrated by a tip of the tube of the implant.
22. A method of implanting an intraocular implant according to claim 18 wherein, in the step of inserting the implant through the sclera, the sclera is penetrated by a needle tip of the delivery device.
23. A method of implanting an intraocular implant into an eyeball comprising the steps of:
attaching the implant to a delivery device;
directing the implant by the delivery device to the implantation site;
inserting the implant through the sclera at the implantation site such that a beveled surface at an inlet end of the implant faces away from the iris; and
withdrawing the delivery device.
24. A method of implanting an intraocular implant into an eyeball comprising the steps of:
attaching the implant to a delivery device;
directing the implant by the delivery device to the implantation site;
inserting the implant through the sclera at the implantation site such that a marker is visible upon penetration through the sclera; and
withdrawing the delivery device.
25. A method of implanting an intraocular implant according to claim 24 wherein the marker comprises a circumferential hole.
26. A method of implanting an intraocular implant into an eyeball comprising the steps of:
attaching the implant to a delivery device;
directing the implant by the delivery device to the implantation site;
inserting the implant through the sclera at the implantation site;
extending outwardly at least one retention projection for anchoring the implant in the eyeball; and
withdrawing the delivery device.
27. A method of implanting an intraocular implant according to claim 26 wherein, in the step of extending outwardly at least one retention projection, at least one retention projection is extended outwardly by an expansion tool when the implant is implanted in the eyeball.
28. A method of implanting an intraocular implant according to claim 26 wherein, in the step of extending outwardly at least one retention projection, at least one retention projection is extended outwardly by the action of a shape memory alloy from which it is constructed when subjected to the heat of the eyeball when the implant is implanted in the eyeball.
29. A method of implanting an intraocular implant into an eyeball comprising the steps of:
attaching the implant to a delivery device comprising a handle and a rodlike instrument comprising a tip for penetrating a tube passage of the implant and a retention mechanism for retaining the implant on the delivery device;
directing the implant by the delivery device to the implantation site;
inserting the implant through the sclera at the implantation site; and
withdrawing the delivery device.
30. A method of implanting an intraocular implant according to claim 29 wherein the retention mechanism comprises an abutment surface for abutting a flanged disk of the implant, wherein the abutment surface has an angle generally corresponding to an angle of the flanged disk.
31. A method of implanting an intraocular implant according to claim 29 further comprising the step of vibrating the delivery device during the step of inserting the implant through the sclera at the implantation site.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/190,740 US20020177856A1 (en) | 1995-05-14 | 2002-07-09 | Intraocular implant, delivery device, and method of implantation |
US10/692,934 US7481816B2 (en) | 1995-05-14 | 2003-10-27 | Intraocular implant, delivery device, and method of implantation |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL11372395A IL113723A (en) | 1995-05-14 | 1995-05-14 | Intraocular implant |
IL113723 | 1995-05-14 | ||
US08/623,238 US5868697A (en) | 1995-05-14 | 1996-03-27 | Intraocular implant |
US08/711,377 US5702414A (en) | 1995-05-14 | 1996-09-05 | Method of implanting an intraocular implant |
US08/891,765 US5968058A (en) | 1996-03-27 | 1997-07-14 | Device for and method of implanting an intraocular implant |
US09/383,472 US6468283B1 (en) | 1995-05-14 | 1999-08-26 | Method of regulating pressure with an intraocular implant |
US10/190,740 US20020177856A1 (en) | 1995-05-14 | 2002-07-09 | Intraocular implant, delivery device, and method of implantation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/383,472 Division US6468283B1 (en) | 1995-05-14 | 1999-08-26 | Method of regulating pressure with an intraocular implant |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/692,934 Division US7481816B2 (en) | 1995-05-14 | 2003-10-27 | Intraocular implant, delivery device, and method of implantation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020177856A1 true US20020177856A1 (en) | 2002-11-28 |
Family
ID=27089400
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/891,765 Expired - Lifetime US5968058A (en) | 1995-05-14 | 1997-07-14 | Device for and method of implanting an intraocular implant |
US09/383,472 Expired - Lifetime US6468283B1 (en) | 1995-05-14 | 1999-08-26 | Method of regulating pressure with an intraocular implant |
US10/190,740 Abandoned US20020177856A1 (en) | 1995-05-14 | 2002-07-09 | Intraocular implant, delivery device, and method of implantation |
US10/692,934 Expired - Fee Related US7481816B2 (en) | 1995-05-14 | 2003-10-27 | Intraocular implant, delivery device, and method of implantation |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/891,765 Expired - Lifetime US5968058A (en) | 1995-05-14 | 1997-07-14 | Device for and method of implanting an intraocular implant |
US09/383,472 Expired - Lifetime US6468283B1 (en) | 1995-05-14 | 1999-08-26 | Method of regulating pressure with an intraocular implant |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/692,934 Expired - Fee Related US7481816B2 (en) | 1995-05-14 | 2003-10-27 | Intraocular implant, delivery device, and method of implantation |
Country Status (1)
Country | Link |
---|---|
US (4) | US5968058A (en) |
Cited By (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050197653A1 (en) * | 2004-03-02 | 2005-09-08 | Sniegowski Jeffry J. | Filter assembly with microfabricated filter element |
US20060281986A1 (en) * | 2005-06-09 | 2006-12-14 | Allergan, Inc. | Apparatus and methods useful for monitoring intraocular pressure |
US20070004998A1 (en) * | 2005-06-21 | 2007-01-04 | Rodgers M S | Glaucoma implant having MEMS flow module with flexing diaphragm for pressure regulation |
US7291125B2 (en) | 2003-11-14 | 2007-11-06 | Transcend Medical, Inc. | Ocular pressure regulation |
US7364564B2 (en) | 2004-03-02 | 2008-04-29 | Becton, Dickinson And Company | Implant having MEMS flow module with movable, flow-controlling baffle |
US20080108933A1 (en) * | 2006-06-30 | 2008-05-08 | Dao-Yi Yu | Methods, Systems and Apparatus for Relieving Pressure in an Organ |
US7384550B2 (en) | 2004-02-24 | 2008-06-10 | Becton, Dickinson And Company | Glaucoma implant having MEMS filter module |
US20080161741A1 (en) * | 2000-01-12 | 2008-07-03 | Becton, Dickinson And Company | Ocular implant and methods for making and using same |
US20080195044A1 (en) * | 2005-03-23 | 2008-08-14 | Akira Nishimura | Ophthalmic Cannula |
US20090043242A1 (en) * | 2007-08-07 | 2009-02-12 | Becton, Dickinson And Company | Instruments and methods for implanting corneal implant via extra-and intra-cameral routes |
US8167939B2 (en) | 2009-01-28 | 2012-05-01 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US20120117807A1 (en) * | 2005-07-25 | 2012-05-17 | Hakko, Co., Ltd. | Ultrasonic piercing needle |
US8308701B2 (en) | 2010-11-15 | 2012-11-13 | Aquesys, Inc. | Methods for deploying intraocular shunts |
US8444588B2 (en) | 2003-05-05 | 2013-05-21 | Transcend Medical, Inc. | Internal shunt and method for treating glaucoma |
US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
AU2006336598B2 (en) * | 2006-01-17 | 2013-10-10 | Alcon Inc. | Glaucoma treatment device |
US8585629B2 (en) | 2010-11-15 | 2013-11-19 | Aquesys, Inc. | Systems for deploying intraocular shunts |
US8617139B2 (en) | 2008-06-25 | 2013-12-31 | Transcend Medical, Inc. | Ocular implant with shape change capabilities |
US8663303B2 (en) | 2010-11-15 | 2014-03-04 | Aquesys, Inc. | Methods for deploying an intraocular shunt from a deployment device and into an eye |
US8672870B2 (en) | 2007-07-17 | 2014-03-18 | Transcend Medical, Inc. | Ocular implant with hydrogel expansion capabilities |
US8721702B2 (en) | 2010-11-15 | 2014-05-13 | Aquesys, Inc. | Intraocular shunt deployment devices |
US8758290B2 (en) | 2010-11-15 | 2014-06-24 | Aquesys, Inc. | Devices and methods for implanting a shunt in the suprachoroidal space |
US8765210B2 (en) | 2011-12-08 | 2014-07-01 | Aquesys, Inc. | Systems and methods for making gelatin shunts |
US8801766B2 (en) | 2010-11-15 | 2014-08-12 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US8828070B2 (en) | 2010-11-15 | 2014-09-09 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US8852137B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for implanting a soft gel shunt in the suprachoroidal space |
US8852256B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for intraocular shunt placement |
US8852136B2 (en) | 2011-12-08 | 2014-10-07 | Aquesys, Inc. | Methods for placing a shunt into the intra-scleral space |
US8974511B2 (en) | 2010-11-15 | 2015-03-10 | Aquesys, Inc. | Methods for treating closed angle glaucoma |
US9017276B2 (en) | 2010-11-15 | 2015-04-28 | Aquesys, Inc. | Shunt placement through the sclera |
US9084662B2 (en) | 2006-01-17 | 2015-07-21 | Transcend Medical, Inc. | Drug delivery treatment device |
US9095411B2 (en) | 2010-11-15 | 2015-08-04 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US9138345B2 (en) | 2003-02-18 | 2015-09-22 | S. K. Pharmaceuticals, Inc. | Optic nerve implants |
US9155656B2 (en) | 2012-04-24 | 2015-10-13 | Transcend Medical, Inc. | Delivery system for ocular implant |
US9480598B2 (en) | 2012-09-17 | 2016-11-01 | Novartis Ag | Expanding ocular implant devices and methods |
US9492320B2 (en) | 1999-04-26 | 2016-11-15 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US9554940B2 (en) | 2012-03-26 | 2017-01-31 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US9561131B2 (en) | 2001-08-28 | 2017-02-07 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US9572963B2 (en) | 2001-04-07 | 2017-02-21 | Glaukos Corporation | Ocular disorder treatment methods and systems |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US9597230B2 (en) | 2002-04-08 | 2017-03-21 | Glaukos Corporation | Devices and methods for glaucoma treatment |
US9610195B2 (en) | 2013-02-27 | 2017-04-04 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
US9763829B2 (en) | 2012-11-14 | 2017-09-19 | Novartis Ag | Flow promoting ocular implant |
US9962290B2 (en) | 2006-11-10 | 2018-05-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
US9993368B2 (en) | 2000-04-14 | 2018-06-12 | Glaukos Corporation | System and method for treating an ocular disorder |
US10080682B2 (en) | 2011-12-08 | 2018-09-25 | Aquesys, Inc. | Intrascleral shunt placement |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US10195079B2 (en) | 2013-02-19 | 2019-02-05 | Aquesys, Inc. | Adjustable intraocular implant |
USD846738S1 (en) | 2017-10-27 | 2019-04-23 | Glaukos Corporation | Implant delivery apparatus |
US10307292B2 (en) | 2011-07-18 | 2019-06-04 | Mor Research Applications Ltd | Device for adjusting the intraocular pressure |
US10369048B2 (en) | 2013-06-28 | 2019-08-06 | Aquesys, Inc. | Intraocular shunt implantation |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US10463537B2 (en) | 2015-06-03 | 2019-11-05 | Aquesys Inc. | Ab externo intraocular shunt placement |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US10842671B2 (en) | 2010-11-15 | 2020-11-24 | Aquesys, Inc. | Intraocular shunt placement in the suprachoroidal space |
US10880754B1 (en) | 2020-05-13 | 2020-12-29 | T-Mobile Usa, Inc. | Network planning tool for retention analysis in telecommunications networks |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
US11223960B2 (en) | 2020-05-13 | 2022-01-11 | T-Mobile Usa, Inc. | Network planning tool for forecasting in telecommunications networks |
US11246753B2 (en) | 2017-11-08 | 2022-02-15 | Aquesys, Inc. | Manually adjustable intraocular flow regulation |
US11376040B2 (en) | 2017-10-06 | 2022-07-05 | Glaukos Corporation | Systems and methods for delivering multiple ocular implants |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968058A (en) | 1996-03-27 | 1999-10-19 | Optonol Ltd. | Device for and method of implanting an intraocular implant |
AUPO394496A0 (en) * | 1996-11-29 | 1997-01-02 | Lions Eye Institute | Biological microfistula tube and implantation method and apparatus |
GB9700390D0 (en) * | 1997-01-10 | 1997-02-26 | Biocompatibles Ltd | Device for use in the eye |
US5853416A (en) * | 1997-06-04 | 1998-12-29 | Boston Scientific Corporation | Distal end for ligating band dispenser |
US8313454B2 (en) | 1997-11-20 | 2012-11-20 | Optonol Ltd. | Fluid drainage device, delivery device, and associated methods of use and manufacture |
US6203513B1 (en) * | 1997-11-20 | 2001-03-20 | Optonol Ltd. | Flow regulating implant, method of manufacture, and delivery device |
US20050119601A9 (en) * | 1999-04-26 | 2005-06-02 | Lynch Mary G. | Shunt device and method for treating glaucoma |
US6558342B1 (en) | 1999-06-02 | 2003-05-06 | Optonol Ltd. | Flow control device, introducer and method of implanting |
US6471666B1 (en) | 2000-02-24 | 2002-10-29 | Steven A. Odrich | Injectable glaucoma device |
US20020143284A1 (en) * | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
US6533768B1 (en) | 2000-04-14 | 2003-03-18 | The Regents Of The University Of California | Device for glaucoma treatment and methods thereof |
US9603741B2 (en) | 2000-05-19 | 2017-03-28 | Michael S. Berlin | Delivery system and method of use for the eye |
US6730056B1 (en) | 2000-09-21 | 2004-05-04 | Motorola, Inc. | Eye implant for treating glaucoma and method for manufacturing same |
US6881198B2 (en) * | 2001-01-09 | 2005-04-19 | J. David Brown | Glaucoma treatment device and method |
US6595945B2 (en) | 2001-01-09 | 2003-07-22 | J. David Brown | Glaucoma treatment device and method |
US7122042B2 (en) * | 2001-03-15 | 2006-10-17 | Lorusso Frank J | Apparatuses and methods for transcleral cautery and subretinal drainage |
US6981958B1 (en) | 2001-05-02 | 2006-01-03 | Glaukos Corporation | Implant with pressure sensor for glaucoma treatment |
US7488303B1 (en) | 2002-09-21 | 2009-02-10 | Glaukos Corporation | Ocular implant with anchor and multiple openings |
US6666841B2 (en) * | 2001-05-02 | 2003-12-23 | Glaukos Corporation | Bifurcatable trabecular shunt for glaucoma treatment |
US7678065B2 (en) | 2001-05-02 | 2010-03-16 | Glaukos Corporation | Implant with intraocular pressure sensor for glaucoma treatment |
WO2002089699A2 (en) | 2001-05-03 | 2002-11-14 | Glaukos Corporation | Medical device and methods of use for glaucoma treatment |
WO2003015667A1 (en) * | 2001-08-03 | 2003-02-27 | David Castillejos | Method and intra sclera implant for treatment of glaucoma and presbyopia |
US20030097151A1 (en) * | 2001-10-25 | 2003-05-22 | Smedley Gregory T. | Apparatus and mitochondrial treatment for glaucoma |
US7163543B2 (en) * | 2001-11-08 | 2007-01-16 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US20030153863A1 (en) * | 2002-02-13 | 2003-08-14 | Patel Anilbhai S. | Implant system for glaucoma surgery |
US7186232B1 (en) | 2002-03-07 | 2007-03-06 | Glaukoa Corporation | Fluid infusion methods for glaucoma treatment |
IL148616A (en) * | 2002-03-11 | 2008-03-20 | Oded Nahleili | Polymeric stent useful for the treatment of the salivary gland ducts |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
EP1539066B1 (en) * | 2002-09-17 | 2012-11-07 | Iscience Surgical Corporation | Apparatus surgical bypass of aqueous humor |
US7160264B2 (en) * | 2002-12-19 | 2007-01-09 | Medtronic-Xomed, Inc. | Article and method for ocular aqueous drainage |
US20040193095A1 (en) * | 2003-03-29 | 2004-09-30 | Shadduck John H. | Implants for treating ocular hypertension, methods of use and methods of fabrication |
US20040236343A1 (en) * | 2003-05-23 | 2004-11-25 | Taylor Jon B. | Insertion tool for ocular implant and method for using same |
JP5009623B2 (en) * | 2003-12-05 | 2012-08-22 | イノレーン リミティド ライアビリティ カンパニー | Improved intraocular lens |
US7431709B2 (en) * | 2003-12-05 | 2008-10-07 | Innfocus, Llc | Glaucoma implant device |
US7226540B2 (en) * | 2004-02-24 | 2007-06-05 | Becton, Dickinson And Company | MEMS filter module |
US20060173399A1 (en) * | 2005-02-01 | 2006-08-03 | Rodgers M S | MEMS flow module with pivoting-type baffle |
US20060036207A1 (en) * | 2004-02-24 | 2006-02-16 | Koonmen James P | System and method for treating glaucoma |
US20060206049A1 (en) * | 2005-03-14 | 2006-09-14 | Rodgers M S | MEMS flow module with piston-type pressure regulating structure |
US20060219627A1 (en) * | 2005-03-31 | 2006-10-05 | Rodgers M S | MEMS filter module with concentric filtering walls |
US8595146B1 (en) | 2004-03-15 | 2013-11-26 | Aol Inc. | Social networking permissions |
WO2005092260A1 (en) * | 2004-03-26 | 2005-10-06 | Molteno Ophthalmic Ltd | Ophthalmic implant for treating glaucoma |
CN1976732A (en) * | 2004-04-29 | 2007-06-06 | i科学外科公司 | Apparatus and method for surgical enhancement of aqueous humor drainage |
US20100173866A1 (en) * | 2004-04-29 | 2010-07-08 | Iscience Interventional Corporation | Apparatus and method for ocular treatment |
US20050267398A1 (en) * | 2004-05-27 | 2005-12-01 | Dimitri Protopsaltis | Glaucoma shunt |
US7862531B2 (en) | 2004-06-25 | 2011-01-04 | Optonol Ltd. | Flow regulating implants |
US20060110429A1 (en) * | 2004-11-24 | 2006-05-25 | Therakine Corporation | Implant for intraocular drug delivery |
US7594899B2 (en) * | 2004-12-03 | 2009-09-29 | Innfocus, Llc | Glaucoma implant device |
US20070118065A1 (en) * | 2004-12-03 | 2007-05-24 | Leonard Pinchuk | Glaucoma Implant Device |
US20070141116A1 (en) * | 2004-12-03 | 2007-06-21 | Leonard Pinchuk | Glaucoma Implant Device |
US7837644B2 (en) * | 2004-12-03 | 2010-11-23 | Innfocus, Llc | Glaucoma implant device |
US20060247664A1 (en) * | 2005-03-08 | 2006-11-02 | California Institute Of Technology | Micromachined tissue anchors for securing implants without sutures |
US20060276738A1 (en) * | 2005-06-06 | 2006-12-07 | Becker Bruce B | Lacrimal drainage bypass device and method |
EP1924306A2 (en) * | 2005-09-16 | 2008-05-28 | BG Implant, Inc. | Glaucoma treatment devices and methods |
US20100241046A1 (en) * | 2006-09-06 | 2010-09-23 | Innfocus, Llc | Apparatus, methods and devices for treatment of ocular disorders |
US20080277332A1 (en) * | 2007-05-11 | 2008-11-13 | Becton, Dickinson And Company | Micromachined membrane filter device for a glaucoma implant and method for making the same |
US8734377B2 (en) | 2007-09-24 | 2014-05-27 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
US20090082862A1 (en) | 2007-09-24 | 2009-03-26 | Schieber Andrew T | Ocular Implant Architectures |
US7740604B2 (en) | 2007-09-24 | 2010-06-22 | Ivantis, Inc. | Ocular implants for placement in schlemm's canal |
US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8512404B2 (en) | 2007-11-20 | 2013-08-20 | Ivantis, Inc. | Ocular implant delivery system and method |
US8109896B2 (en) | 2008-02-11 | 2012-02-07 | Optonol Ltd. | Devices and methods for opening fluid passageways |
CN101965211A (en) | 2008-03-05 | 2011-02-02 | 伊万提斯公司 | Methods and apparatus for treating glaucoma |
NL2001401C2 (en) * | 2008-03-25 | 2009-09-28 | D O R C Dutch Ophthalmic Res C | Eye surgical instrument. |
WO2010065970A1 (en) | 2008-12-05 | 2010-06-10 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8425473B2 (en) | 2009-01-23 | 2013-04-23 | Iscience Interventional Corporation | Subretinal access device |
US20100191177A1 (en) * | 2009-01-23 | 2010-07-29 | Iscience Interventional Corporation | Device for aspirating fluids |
US8623040B2 (en) | 2009-07-01 | 2014-01-07 | Alcon Research, Ltd. | Phacoemulsification hook tip |
AU2010271274B2 (en) | 2009-07-09 | 2015-05-21 | Alcon Inc. | Single operator device for delivering an ocular implant |
JP5635605B2 (en) | 2009-07-09 | 2014-12-03 | イバンティス インコーポレイテッド | Intraocular implant and method for delivering an intraocular implant into an eyeball |
US8535333B2 (en) * | 2009-07-29 | 2013-09-17 | Transcend Medical, Inc. | Ocular implant applier and methods of use |
US8545431B2 (en) * | 2009-09-21 | 2013-10-01 | Alcon Research, Ltd. | Lumen clearing valve for glaucoma drainage device |
US8419673B2 (en) | 2009-09-21 | 2013-04-16 | Alcon Research, Ltd. | Glaucoma drainage device with pump |
US8257295B2 (en) | 2009-09-21 | 2012-09-04 | Alcon Research, Ltd. | Intraocular pressure sensor with external pressure compensation |
US8721580B2 (en) * | 2009-09-21 | 2014-05-13 | Alcon Research, Ltd. | Power saving glaucoma drainage device |
WO2011050360A1 (en) | 2009-10-23 | 2011-04-28 | Ivantis, Inc. | Ocular implant system and method |
EP2501428B1 (en) * | 2009-11-18 | 2016-07-06 | Ruben A. Quintero | Fetal shunt |
WO2011087577A1 (en) | 2009-12-23 | 2011-07-21 | Alcon Research, Ltd. | Ophthalmic valved trocar cannula |
US8343106B2 (en) | 2009-12-23 | 2013-01-01 | Alcon Research, Ltd. | Ophthalmic valved trocar vent |
WO2011089605A2 (en) * | 2010-01-22 | 2011-07-28 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Ocular shunt |
US9510973B2 (en) | 2010-06-23 | 2016-12-06 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
US10258505B2 (en) | 2010-09-17 | 2019-04-16 | Alcon Research, Ltd. | Balanced phacoemulsification tip |
US9370444B2 (en) | 2010-10-12 | 2016-06-21 | Emmett T. Cunningham, JR. | Subconjunctival conformer device and uses thereof |
US8915877B2 (en) | 2010-10-12 | 2014-12-23 | Emmett T. Cunningham, JR. | Glaucoma drainage device and uses thereof |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
EP4193907A1 (en) | 2011-09-13 | 2023-06-14 | Glaukos Corporation | Intraocular physiological sensor |
US8585631B2 (en) | 2011-10-18 | 2013-11-19 | Alcon Research, Ltd. | Active bimodal valve system for real-time IOP control |
US8840578B2 (en) | 2011-12-09 | 2014-09-23 | Alcon Research, Ltd. | Multilayer membrane actuators |
US8579848B2 (en) | 2011-12-09 | 2013-11-12 | Alcon Research, Ltd. | Active drainage systems with pressure-driven valves and electronically-driven pump |
US9622910B2 (en) | 2011-12-12 | 2017-04-18 | Alcon Research, Ltd. | Active drainage systems with dual-input pressure-driven values |
US8603024B2 (en) | 2011-12-12 | 2013-12-10 | Alcon Research, Ltd. | Glaucoma drainage devices including vario-stable valves and associated systems and methods |
US9125721B2 (en) | 2011-12-13 | 2015-09-08 | Alcon Research, Ltd. | Active drainage systems with dual-input pressure-driven valves |
US9339187B2 (en) | 2011-12-15 | 2016-05-17 | Alcon Research, Ltd. | External pressure measurement system and method for an intraocular implant |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US9101444B2 (en) | 2012-01-12 | 2015-08-11 | Innfocus, Inc. | Method, surgical kit and device for treating glaucoma |
DE102012200411A1 (en) * | 2012-01-12 | 2013-07-18 | Geuder Ag | Device for use in glaucoma surgery |
WO2013123000A1 (en) | 2012-02-13 | 2013-08-22 | Iridex Corporation | Reduction of intraocular pressure in the eye using a tubular clip |
US9155653B2 (en) | 2012-02-14 | 2015-10-13 | Alcon Research, Ltd. | Pressure-driven membrane valve for pressure control system |
US8986240B2 (en) | 2012-02-14 | 2015-03-24 | Alcon Research, Ltd. | Corrugated membrane actuators |
US8998838B2 (en) | 2012-03-29 | 2015-04-07 | Alcon Research, Ltd. | Adjustable valve for IOP control with reed valve |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US8858491B2 (en) * | 2012-05-23 | 2014-10-14 | Alcon Research, Ltd. | Pre-biased membrane valve |
RU2644926C2 (en) | 2012-06-14 | 2018-02-14 | СЕНОКУЛИС ЛТД. МАЛАТ билдинг | Medical appliance, device and method for channel formation in soft tissues |
US8652085B2 (en) | 2012-07-02 | 2014-02-18 | Alcon Research, Ltd. | Reduction of gas escape in membrane actuators |
US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US9528633B2 (en) | 2012-12-17 | 2016-12-27 | Novartis Ag | MEMS check valve |
US9572712B2 (en) | 2012-12-17 | 2017-02-21 | Novartis Ag | Osmotically actuated fluidic valve |
US9295389B2 (en) | 2012-12-17 | 2016-03-29 | Novartis Ag | Systems and methods for priming an intraocular pressure sensor in an intraocular implant |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
US9226851B2 (en) | 2013-08-24 | 2016-01-05 | Novartis Ag | MEMS check valve chip and methods |
US9283115B2 (en) | 2013-08-26 | 2016-03-15 | Novartis Ag | Passive to active staged drainage device |
US9289324B2 (en) | 2013-08-26 | 2016-03-22 | Novartis Ag | Externally adjustable passive drainage device |
WO2015102965A2 (en) * | 2013-12-30 | 2015-07-09 | Ryan Edwin | Cannula tool and method |
US9681983B2 (en) | 2014-03-13 | 2017-06-20 | Novartis Ag | Debris clearance system for an ocular implant |
US9603742B2 (en) | 2014-03-13 | 2017-03-28 | Novartis Ag | Remote magnetic driven flow system |
JP2017520327A (en) * | 2014-07-01 | 2017-07-27 | インジェクトセンス, インコーポレイテッド | Method and device for implanting an intraocular pressure sensor |
US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
EP3240510A4 (en) | 2014-12-31 | 2018-09-19 | Microoptx Inc. | Glaucoma treatment devices and methods |
US9655777B2 (en) | 2015-04-07 | 2017-05-23 | Novartis Ag | System and method for diagphragm pumping using heating element |
CN108135470B (en) | 2015-08-14 | 2021-03-09 | 伊万提斯公司 | Ocular implant with pressure sensor and delivery system |
EP3355983A4 (en) | 2015-09-30 | 2019-06-26 | Microoptx Inc. | Dry eye treatment devices and methods |
US11938058B2 (en) | 2015-12-15 | 2024-03-26 | Alcon Inc. | Ocular implant and delivery system |
WO2018165467A1 (en) | 2017-03-08 | 2018-09-13 | Sirianni Peter A | Precision steerable and angled medication delivery system |
IL251684B (en) | 2017-04-09 | 2019-01-31 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Device and method for creating a channel in soft tissue |
EP3973933A1 (en) | 2019-06-26 | 2022-03-30 | Imvalv S.A. | Glaucoma drain implant system with pressure sensor and valve, and external reading unit |
IT201900023106A1 (en) * | 2019-12-05 | 2021-06-05 | Paolo Cecchini | PERFECTED MEDICAL DEVICE FOR GLAUCOMA SURGERY AND WITH CONTROLLED AND MODULABLE FILTRATION |
WO2022150684A1 (en) | 2021-01-11 | 2022-07-14 | Ivantis, Inc. | Systems and methods for viscoelastic delivery |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US34998A (en) * | 1862-04-15 | Improvement in coal-sifters | ||
US274447A (en) * | 1883-03-20 | William-kentish | ||
US15192A (en) * | 1856-06-24 | Tubular | ||
US733152A (en) * | 1902-08-30 | 1903-07-07 | Murdoch Chisholm | Empyema drainage device. |
US1388172A (en) * | 1920-03-18 | 1921-08-23 | Simon M Craddock | Veterinary surgical appliance |
US2431587A (en) * | 1945-02-19 | 1947-11-25 | Charles F Schnee | Cannula button for surgical operations and method of use |
US2555076A (en) * | 1947-11-17 | 1951-05-29 | Elijah R Crossley | Instrument for use in performing surgical eye operations |
US2867213A (en) * | 1957-06-12 | 1959-01-06 | Jr Paul A Thomas | Flutter valve for drainage of the pleural cavity |
US3159161A (en) * | 1962-11-14 | 1964-12-01 | Ness Richard Alton | Fistulizing canaliculus |
US3310051A (en) * | 1963-12-10 | 1967-03-21 | Rudolf R Schulte | Surgical reservoir for implantation beneath the skin |
US3333588A (en) * | 1964-07-06 | 1967-08-01 | Rudolf R Schulte | Brain ventricle cannula |
US3272204A (en) * | 1965-09-22 | 1966-09-13 | Ethicon Inc | Absorbable collagen prosthetic implant with non-absorbable reinforcing strands |
US3421509A (en) * | 1965-12-17 | 1969-01-14 | John M Fiore | Urethral catheter |
US3530860A (en) * | 1967-01-09 | 1970-09-29 | Ponce De Leon Ear | Method and apparatus for inserting a tube through the ear drum |
US3589401A (en) * | 1969-07-18 | 1971-06-29 | Case Co J I | Pressure modulating valve |
US3915172A (en) * | 1970-05-27 | 1975-10-28 | Ceskoslovenska Akademie Ved | Capillary drain for glaucoma |
US3788327A (en) * | 1971-03-30 | 1974-01-29 | H Donowitz | Surgical implant device |
US3884238A (en) * | 1972-06-19 | 1975-05-20 | Malley Conor C O | Apparatus for intraocular surgery |
US3957035A (en) * | 1972-09-08 | 1976-05-18 | Jean Chassaing | Ophthalmological device useful for eye surgery |
US3890976A (en) * | 1972-10-26 | 1975-06-24 | Medical Products Corp | Catheter tip assembly |
US3913584A (en) * | 1974-06-28 | 1975-10-21 | Xomox Corp | Combination myringotomy scalpel, aspirator and otological vent tube inserter |
US3938529A (en) * | 1974-07-22 | 1976-02-17 | Gibbons Robert P | Indwelling ureteral catheter |
US4142526A (en) * | 1974-12-23 | 1979-03-06 | Alza Corporation | Osmotic releasing system with means for changing release therefrom |
US3976077A (en) * | 1975-02-03 | 1976-08-24 | Kerfoot Jr Franklin W | Eye surgery device |
US4037604A (en) * | 1976-01-05 | 1977-07-26 | Newkirk John B | Artifical biological drainage device |
US4153058A (en) * | 1977-07-05 | 1979-05-08 | Nehme Alexander E | Pleural decompression catheter |
US4175563A (en) * | 1977-10-05 | 1979-11-27 | Arenberg Irving K | Biological drainage shunt |
US4290426A (en) * | 1978-05-04 | 1981-09-22 | Alza Corporation | Dispenser for dispensing beneficial agent |
US4299227A (en) * | 1979-10-19 | 1981-11-10 | Lincoff Harvey A | Ophthalmological appliance |
US4303063A (en) | 1980-03-06 | 1981-12-01 | Stahl Norman O | Ocular massage device |
US4808183A (en) * | 1980-06-03 | 1989-02-28 | University Of Iowa Research Foundation | Voice button prosthesis and method for installing same |
US4402681A (en) * | 1980-08-23 | 1983-09-06 | Haas Joseph S | Artificial implant valve for the regulation of intraocular pressure |
US4457757A (en) * | 1981-07-20 | 1984-07-03 | Molteno Anthony C B | Device for draining aqueous humour |
FR2514852B1 (en) * | 1981-10-19 | 1985-09-27 | Snecma | FLUID DISPENSING MEMBER AND METHOD FOR PRODUCING THE BODY OF THIS MEMBER |
US4474569A (en) * | 1982-06-28 | 1984-10-02 | Denver Surgical Developments, Inc. | Antenatal shunt |
US4554918A (en) * | 1982-07-28 | 1985-11-26 | White Thomas C | Ocular pressure relief device |
US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
IT8352816V0 (en) * | 1983-01-07 | 1983-01-07 | Ferrando Ugo Gardi Giovanni E | SURGICAL MEDICAL APPLICATION CATHETER |
HU187011B (en) | 1983-01-14 | 1985-10-28 | Orvosi Mueszer Sz | Trachea canula |
US4538611A (en) * | 1983-06-13 | 1985-09-03 | Kelman Charles D | Surgical instrument and method of cutting a lens of an eye |
NL8302541A (en) * | 1983-07-15 | 1985-02-01 | Philips Nv | METHOD FOR MANUFACTURING A SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE MADE ACCORDING TO THE METHOD |
US4587954A (en) * | 1983-12-29 | 1986-05-13 | Habley Medical Technology Corporation | Elastomeric prosthetic sphincter |
US4563779A (en) * | 1984-01-27 | 1986-01-14 | Kelman Charles D | Corneal implant and method of making the same |
US4578058A (en) * | 1984-04-02 | 1986-03-25 | Grandon Stanley C | Intraocular catheter apparatus and method of use |
US4787885A (en) * | 1984-04-06 | 1988-11-29 | Binder Perry S | Hydrogel seton |
US4634418A (en) * | 1984-04-06 | 1987-01-06 | Binder Perry S | Hydrogel seton |
US4660546A (en) * | 1984-11-07 | 1987-04-28 | Robert S. Herrick | Method for treating for deficiency of tears |
US4604087A (en) * | 1985-02-26 | 1986-08-05 | Joseph Neil H | Aqueous humor drainage device |
US4781675A (en) * | 1985-11-27 | 1988-11-01 | White Thomas C | Infusion cannula |
US4692142A (en) * | 1986-02-24 | 1987-09-08 | Dignam Bernard J | Sutureless infusion cannula for ophthalmic surgery |
US4792336A (en) * | 1986-03-03 | 1988-12-20 | American Cyanamid Company | Flat braided ligament or tendon implant device having texturized yarns |
NZ215409A (en) * | 1986-03-07 | 1989-02-24 | Anthony Christopher Be Molteno | Implant for drainage of aqueous humour in glaucoma |
US4964850A (en) * | 1986-05-07 | 1990-10-23 | Vincent Bouton | Method for treating trans-nasal sinus afflictions using a double t-shaped trans-nasal aerator |
US4722724A (en) * | 1986-06-23 | 1988-02-02 | Stanley Schocket | Anterior chamber tube shunt to an encircling band, and related surgical procedure |
US4826478A (en) * | 1986-06-23 | 1989-05-02 | Stanley Schocket | Anterior chamber tube shunt to an encircling band, and related surgical procedure |
US4909783A (en) * | 1986-07-16 | 1990-03-20 | Morrison David P | Intra-ocular pressure apparatus |
US4751926A (en) * | 1986-09-12 | 1988-06-21 | Dow Corning Wright Corporation | Instrument for subcutaneous insertion of an injection reservoir |
US4863457A (en) * | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
US4886488A (en) * | 1987-08-06 | 1989-12-12 | White Thomas C | Glaucoma drainage the lacrimal system and method |
US5139502A (en) * | 1987-08-19 | 1992-08-18 | Atos Medical Ab | Drainage tube for sinus maxillaris, a means for its insertion and a means for making a hole for its positioning |
US4813941A (en) * | 1987-09-03 | 1989-03-21 | Leslie Shea | Pneumothorax treatment device |
US4934363A (en) * | 1987-12-15 | 1990-06-19 | Iolab Corporation | Lens insertion instrument |
US4888016A (en) | 1988-02-10 | 1989-12-19 | Langerman David W | "Spare parts" for use in ophthalmic surgical procedures |
US4936825A (en) * | 1988-04-11 | 1990-06-26 | Ungerleider Bruce A | Method for reducing intraocular pressure caused by glaucoma |
US5098393A (en) * | 1988-05-31 | 1992-03-24 | Kurt Amplatz | Medical introducer and valve assembly |
US4915684A (en) * | 1988-06-21 | 1990-04-10 | Mackeen Donald L | Method and apparatus for modulating the flow of lacrimal fluid through a punctum and associated canaliculus |
US5071408A (en) * | 1988-10-07 | 1991-12-10 | Ahmed Abdul Mateen | Medical valve |
IT1227176B (en) * | 1988-10-11 | 1991-03-20 | Co Pharma Corp Srl | DEVICE FOR FIXING A CATHETER TO THE CRANIAL TECA FOR EXTERNAL LIQUOR DERIVATION |
US4959048A (en) * | 1989-01-17 | 1990-09-25 | Helix Medical, Inc. | Lacrimal duct occluder |
US5000731A (en) * | 1989-03-30 | 1991-03-19 | Tai-Ting Wong | Shunting device adopted in the intracranial shunting surgical operation for the treatment of hydrocephalus |
US5053040A (en) * | 1989-11-09 | 1991-10-01 | Goldsmith Iii Manning M | Method of performing a myringotomy |
US4946436A (en) * | 1989-11-17 | 1990-08-07 | Smith Stewart G | Pressure-relieving device and process for implanting |
US5167620A (en) * | 1989-11-28 | 1992-12-01 | Alexandar Ureche | Eye surgery methods |
US5106367A (en) * | 1989-11-28 | 1992-04-21 | Alexander Ureche | Eye surgery apparatus with vacuum surge suppressor |
RU1797884C (en) | 1989-11-30 | 1993-02-28 | Туркменский Научно-Исследовательский Институт Глазных Болезней | Artificial implanted valve for adjustment of intraocular pressure |
US5092837A (en) * | 1989-12-20 | 1992-03-03 | Robert Ritch | Method for the treatment of glaucoma |
US4968296A (en) * | 1989-12-20 | 1990-11-06 | Robert Ritch | Transscleral drainage implant device for the treatment of glaucoma |
US5073163A (en) * | 1990-01-29 | 1991-12-17 | Lippman Myron E | Apparatus for treating glaucoma |
US5171270A (en) | 1990-03-29 | 1992-12-15 | Herrick Robert S | Canalicular implant having a collapsible flared section and method |
US5127901A (en) * | 1990-05-18 | 1992-07-07 | Odrich Ronald B | Implant with subconjunctival arch |
US5041081A (en) * | 1990-05-18 | 1991-08-20 | Odrich Ronald B | Ocular implant for controlling glaucoma |
US5178604A (en) * | 1990-05-31 | 1993-01-12 | Iovision, Inc. | Glaucoma implant |
US5476445A (en) * | 1990-05-31 | 1995-12-19 | Iovision, Inc. | Glaucoma implant with a temporary flow restricting seal |
US5397300A (en) * | 1990-05-31 | 1995-03-14 | Iovision, Inc. | Glaucoma implant |
US5098438A (en) * | 1990-08-23 | 1992-03-24 | Siepser Steven B | Procedures for intraocular surgery |
US5454796A (en) * | 1991-04-09 | 1995-10-03 | Hood Laboratories | Device and method for controlling intraocular fluid pressure |
US5242449A (en) * | 1991-04-23 | 1993-09-07 | Allergan, Inc. | Ophthalmic instrument |
US5207660A (en) * | 1991-04-26 | 1993-05-04 | Cornell Research Foundation, Inc. | Method for the delivery of compositions to the ocular tissues |
US5358492A (en) | 1991-05-02 | 1994-10-25 | Feibus Miriam H | Woven surgical drain and method of making |
US6007511A (en) * | 1991-05-08 | 1999-12-28 | Prywes; Arnold S. | Shunt valve and therapeutic delivery system for treatment of glaucoma and methods and apparatus for its installation |
US5300020A (en) * | 1991-05-31 | 1994-04-05 | Medflex Corporation | Surgically implantable device for glaucoma relief |
US5147370A (en) * | 1991-06-12 | 1992-09-15 | Mcnamara Thomas O | Nitinol stent for hollow body conduits |
US5326345A (en) * | 1991-08-14 | 1994-07-05 | Price Jr Francis W | Eye filtration prostheses |
US5171213A (en) * | 1991-08-14 | 1992-12-15 | Price Jr Francis W | Technique for fistulization of the eye and an eye filtration prosthesis useful therefor |
US5360399A (en) * | 1992-01-10 | 1994-11-01 | Robert Stegmann | Method and apparatus for maintaining the normal intraocular pressure |
AU681575B2 (en) * | 1992-01-29 | 1997-09-04 | Stewart Gregory Smith | Method and apparatus for phaco-emulsification |
US5283063A (en) * | 1992-01-31 | 1994-02-01 | Eagle Vision | Punctum plug method and apparatus |
US5190552A (en) * | 1992-02-04 | 1993-03-02 | Kelman Charles D | Slotted tube injector for an intraocular lens |
US5217486A (en) * | 1992-02-18 | 1993-06-08 | Mitek Surgical Products, Inc. | Suture anchor and installation tool |
US5346464A (en) * | 1992-03-10 | 1994-09-13 | Camras Carl B | Method and apparatus for reducing intraocular pressure |
US5221278A (en) * | 1992-03-12 | 1993-06-22 | Alza Corporation | Osmotically driven delivery device with expandable orifice for pulsatile delivery effect |
WO1993020783A1 (en) * | 1992-04-13 | 1993-10-28 | Iovision, Inc. | Glaucoma implant |
US5380290A (en) * | 1992-04-16 | 1995-01-10 | Pfizer Hospital Products Group, Inc. | Body access device |
US5322504A (en) * | 1992-05-07 | 1994-06-21 | United States Surgical Corporation | Method and apparatus for tissue excision and removal by fluid jet |
WO1994002081A1 (en) * | 1992-07-16 | 1994-02-03 | Wong Vernon G | Eye implant suitable for relief of glaucoma |
US5238063A (en) * | 1992-08-04 | 1993-08-24 | Masx Energy Services Group, Inc. | Pressure balanced charge container for wellhead severing system |
WO1994007436A1 (en) * | 1992-09-30 | 1994-04-14 | Vladimir Feingold | Intraocular lens insertion system |
US5370607A (en) * | 1992-10-28 | 1994-12-06 | Annuit Coeptis, Inc. | Glaucoma implant device and method for implanting same |
EP0596314B1 (en) * | 1992-11-06 | 1999-12-15 | GRIESHABER & CO. AG | Ophthalmological aspiration and irrigation device |
WO1994013234A1 (en) * | 1992-12-17 | 1994-06-23 | Michael Andrew Coote | Implant device and method for treatment of glaucoma |
US5338291A (en) * | 1993-02-03 | 1994-08-16 | Pudenz-Schulte Medical Research Corporation | Glaucoma shunt and method for draining aqueous humor |
USD356867S (en) | 1993-03-10 | 1995-03-28 | Hood Laboratories | Device for controlling intraocular fluid pressure |
US5342370A (en) * | 1993-03-19 | 1994-08-30 | University Of Miami | Method and apparatus for implanting an artifical meshwork in glaucoma surgery |
US5433714A (en) * | 1993-04-06 | 1995-07-18 | Bloomberg; Leroy | Topical anesthesia method for eye surgery, and applicator therefor |
DE4313245C2 (en) * | 1993-04-23 | 1997-03-27 | Geuder Hans Gmbh | Hollow needle for an ophthalmic surgical instrument |
IL109499A (en) | 1994-05-02 | 1998-01-04 | Univ Ramot | Implant device for draining excess intraocular fluid |
FR2721499B1 (en) * | 1994-06-22 | 1997-01-03 | Opsia | Trabeculectomy implant. |
US5520631A (en) * | 1994-07-22 | 1996-05-28 | Wound Healing Of Oklahoma | Method and apparatus for lowering the intraocular pressure of an eye |
US6102045A (en) * | 1994-07-22 | 2000-08-15 | Premier Laser Systems, Inc. | Method and apparatus for lowering the intraocular pressure of an eye |
US5704907A (en) * | 1994-07-22 | 1998-01-06 | Wound Healing Of Oklahoma | Method and apparatus for lowering the intraocular pressure of an eye |
US5522845A (en) * | 1994-09-27 | 1996-06-04 | Mitek Surgical Products, Inc. | Bone anchor and bone anchor installation |
US5601094A (en) * | 1994-11-22 | 1997-02-11 | Reiss; George R. | Ophthalmic shunt |
US5660205A (en) * | 1994-12-15 | 1997-08-26 | Epstein; Alan B. | One-way valve |
US5433701A (en) * | 1994-12-21 | 1995-07-18 | Rubinstein; Mark H. | Apparatus for reducing ocular pressure |
US5558630A (en) * | 1994-12-30 | 1996-09-24 | Fisher; Bret L. | Intrascleral implant and method for the regulation of intraocular pressure |
US5626558A (en) * | 1995-05-05 | 1997-05-06 | Suson; John | Adjustable flow rate glaucoma shunt and method of using same |
AU5857396A (en) | 1995-05-14 | 1996-11-29 | Optonol Ltd. | Intraocular implant, delivery device, and method of implanta tion |
US5968058A (en) | 1996-03-27 | 1999-10-19 | Optonol Ltd. | Device for and method of implanting an intraocular implant |
IL113723A (en) | 1995-05-14 | 2002-11-10 | Optonol Ltd | Intraocular implant |
US5662600A (en) | 1995-09-29 | 1997-09-02 | Pudenz-Schulte Medical Research Corporation | Burr-hole flow control device |
US5741292A (en) * | 1995-10-26 | 1998-04-21 | Eagle Vision | Punctum dilating and plug inserting instrument with push-button plug release |
US5709698A (en) | 1996-02-26 | 1998-01-20 | Linvatec Corporation | Irrigating/aspirating shaver blade assembly |
US5665101A (en) | 1996-04-01 | 1997-09-09 | Linvatec Corporation | Endoscopic or open lipectomy instrument |
US5865831A (en) * | 1996-04-17 | 1999-02-02 | Premier Laser Systems, Inc. | Laser surgical procedures for treatment of glaucoma |
US5980480A (en) * | 1996-07-11 | 1999-11-09 | Cs Fluids, Inc. | Method and apparatus for treating adult-onset dementia of the alzheimer's type |
US5807240A (en) | 1996-09-24 | 1998-09-15 | Circon Corporation | Continuous flow endoscope with enlarged outflow channel |
FR2757068B1 (en) | 1996-12-13 | 1999-04-23 | Jussmann Alberto | SELF-FIXING DRAIN |
GB9700390D0 (en) | 1997-01-10 | 1997-02-26 | Biocompatibles Ltd | Device for use in the eye |
US5713844A (en) | 1997-01-10 | 1998-02-03 | Peyman; Gholam A. | Device and method for regulating intraocular pressure |
US5893837A (en) * | 1997-02-28 | 1999-04-13 | Staar Surgical Company, Inc. | Glaucoma drain implanting device and method |
US6050970A (en) * | 1997-05-08 | 2000-04-18 | Pharmacia & Upjohn Company | Method and apparatus for inserting a glaucoma implant in an anterior and posterior segment of the eye |
US6007578A (en) * | 1997-10-08 | 1999-12-28 | Ras Holding Corp | Scleral prosthesis for treatment of presbyopia and other eye disorders |
US6168575B1 (en) * | 1998-01-29 | 2001-01-02 | David Pyam Soltanpour | Method and apparatus for controlling intraocular pressure |
US6221078B1 (en) * | 1999-06-25 | 2001-04-24 | Stephen S. Bylsma | Surgical implantation apparatus |
-
1997
- 1997-07-14 US US08/891,765 patent/US5968058A/en not_active Expired - Lifetime
-
1999
- 1999-08-26 US US09/383,472 patent/US6468283B1/en not_active Expired - Lifetime
-
2002
- 2002-07-09 US US10/190,740 patent/US20020177856A1/en not_active Abandoned
-
2003
- 2003-10-27 US US10/692,934 patent/US7481816B2/en not_active Expired - Fee Related
Cited By (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9492320B2 (en) | 1999-04-26 | 2016-11-15 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US10492950B2 (en) | 1999-04-26 | 2019-12-03 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US9827143B2 (en) | 1999-04-26 | 2017-11-28 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US10568762B2 (en) | 1999-04-26 | 2020-02-25 | Glaukos Corporation | Stent for treating ocular disorders |
US20080161741A1 (en) * | 2000-01-12 | 2008-07-03 | Becton, Dickinson And Company | Ocular implant and methods for making and using same |
US10485702B2 (en) | 2000-04-14 | 2019-11-26 | Glaukos Corporation | System and method for treating an ocular disorder |
US9993368B2 (en) | 2000-04-14 | 2018-06-12 | Glaukos Corporation | System and method for treating an ocular disorder |
US9572963B2 (en) | 2001-04-07 | 2017-02-21 | Glaukos Corporation | Ocular disorder treatment methods and systems |
US9987472B2 (en) | 2001-04-07 | 2018-06-05 | Glaukos Corporation | Ocular implant delivery systems |
US10828473B2 (en) | 2001-04-07 | 2020-11-10 | Glaukos Corporation | Ocular implant delivery system and methods thereof |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US10285856B2 (en) | 2001-08-28 | 2019-05-14 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US9561131B2 (en) | 2001-08-28 | 2017-02-07 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US9597230B2 (en) | 2002-04-08 | 2017-03-21 | Glaukos Corporation | Devices and methods for glaucoma treatment |
US10485701B2 (en) | 2002-04-08 | 2019-11-26 | Glaukos Corporation | Devices and methods for glaucoma treatment |
US9138345B2 (en) | 2003-02-18 | 2015-09-22 | S. K. Pharmaceuticals, Inc. | Optic nerve implants |
US8945038B2 (en) | 2003-05-05 | 2015-02-03 | Transcend Medical, Inc. | Internal shunt and method for treating glaucoma |
US9844462B2 (en) | 2003-05-05 | 2017-12-19 | Novartis Ag | Internal shunt and method for treating glaucoma |
US8444588B2 (en) | 2003-05-05 | 2013-05-21 | Transcend Medical, Inc. | Internal shunt and method for treating glaucoma |
US8808220B2 (en) | 2003-11-14 | 2014-08-19 | Transcend Medical, Inc. | Ocular pressure regulation |
US10226380B2 (en) | 2003-11-14 | 2019-03-12 | Novartis Ag | Ocular pressure regulation |
US8758289B2 (en) | 2003-11-14 | 2014-06-24 | Transcend Medical, Inc. | Ocular pressure regulation |
US9351873B2 (en) | 2003-11-14 | 2016-05-31 | Transcend Medical, Inc. | Ocular pressure regulation |
US8486000B2 (en) | 2003-11-14 | 2013-07-16 | Transcend Medical, Inc. | Ocular pressure regulation |
US7815592B2 (en) | 2003-11-14 | 2010-10-19 | Transcend Medical, Inc. | Ocular pressure regulation |
US7850638B2 (en) | 2003-11-14 | 2010-12-14 | Transcend Medical, Inc. | Ocular pressure regulation |
US8771218B2 (en) | 2003-11-14 | 2014-07-08 | Transcend Medical, Inc. | Ocular pressure regulation |
US7291125B2 (en) | 2003-11-14 | 2007-11-06 | Transcend Medical, Inc. | Ocular pressure regulation |
US8128588B2 (en) | 2003-11-14 | 2012-03-06 | Transcend Medical, Inc. | Ocular pressure regulation |
US8728021B2 (en) | 2003-11-14 | 2014-05-20 | Transcend Medical, Inc. | Ocular pressure regulation |
US7384550B2 (en) | 2004-02-24 | 2008-06-10 | Becton, Dickinson And Company | Glaucoma implant having MEMS filter module |
US7364564B2 (en) | 2004-03-02 | 2008-04-29 | Becton, Dickinson And Company | Implant having MEMS flow module with movable, flow-controlling baffle |
US20050197653A1 (en) * | 2004-03-02 | 2005-09-08 | Sniegowski Jeffry J. | Filter assembly with microfabricated filter element |
US20080195044A1 (en) * | 2005-03-23 | 2008-08-14 | Akira Nishimura | Ophthalmic Cannula |
US20060281986A1 (en) * | 2005-06-09 | 2006-12-14 | Allergan, Inc. | Apparatus and methods useful for monitoring intraocular pressure |
US20070004998A1 (en) * | 2005-06-21 | 2007-01-04 | Rodgers M S | Glaucoma implant having MEMS flow module with flexing diaphragm for pressure regulation |
US7544176B2 (en) | 2005-06-21 | 2009-06-09 | Becton, Dickinson And Company | Glaucoma implant having MEMS flow module with flexing diaphragm for pressure regulation |
US20120117807A1 (en) * | 2005-07-25 | 2012-05-17 | Hakko, Co., Ltd. | Ultrasonic piercing needle |
US8721656B2 (en) | 2006-01-17 | 2014-05-13 | Transcend Medical, Inc. | Glaucoma treatment device |
US10905590B2 (en) | 2006-01-17 | 2021-02-02 | Alcon Inc. | Glaucoma treatment device |
US8801649B2 (en) | 2006-01-17 | 2014-08-12 | Transcend Medical, Inc. | Glaucoma treatment device |
US9668917B2 (en) | 2006-01-17 | 2017-06-06 | Novartis Ag | Drug delivery treatment device |
US8814819B2 (en) | 2006-01-17 | 2014-08-26 | Transcend Medical, Inc. | Glaucoma treatment device |
US11786402B2 (en) | 2006-01-17 | 2023-10-17 | Alcon Inc. | Glaucoma treatment device |
US9789000B2 (en) | 2006-01-17 | 2017-10-17 | Novartis Ag | Glaucoma treatment device |
US9398977B2 (en) | 2006-01-17 | 2016-07-26 | Transcend Medical, Inc. | Glaucoma treatment device |
US8734378B2 (en) | 2006-01-17 | 2014-05-27 | Transcend Medical, Inc. | Glaucoma treatment device |
US9084662B2 (en) | 2006-01-17 | 2015-07-21 | Transcend Medical, Inc. | Drug delivery treatment device |
AU2006336598B2 (en) * | 2006-01-17 | 2013-10-10 | Alcon Inc. | Glaucoma treatment device |
US9421130B2 (en) | 2006-01-17 | 2016-08-23 | Novartis Ag. | Glaucoma treatment device |
US20080108933A1 (en) * | 2006-06-30 | 2008-05-08 | Dao-Yi Yu | Methods, Systems and Apparatus for Relieving Pressure in an Organ |
US20100121248A1 (en) * | 2006-06-30 | 2010-05-13 | Aquesys, Inc. | Apparatus for reducing pressure in an organ |
US20100119696A1 (en) * | 2006-06-30 | 2010-05-13 | Aquesys, Inc. | Manufacture of an organ implant |
US9636254B2 (en) | 2006-06-30 | 2017-05-02 | Aquesys, Inc. | Systems for reducing pressure in an organ |
US10828195B2 (en) | 2006-11-10 | 2020-11-10 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9962290B2 (en) | 2006-11-10 | 2018-05-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US8672870B2 (en) | 2007-07-17 | 2014-03-18 | Transcend Medical, Inc. | Ocular implant with hydrogel expansion capabilities |
US9585789B2 (en) | 2007-07-17 | 2017-03-07 | Novartis Ag | Ocular implant with hydrogel expansion capabilities |
US20090043242A1 (en) * | 2007-08-07 | 2009-02-12 | Becton, Dickinson And Company | Instruments and methods for implanting corneal implant via extra-and intra-cameral routes |
US10016301B2 (en) | 2008-06-25 | 2018-07-10 | Novartis Ag | Ocular implant with shape change capabilities |
US8617139B2 (en) | 2008-06-25 | 2013-12-31 | Transcend Medical, Inc. | Ocular implant with shape change capabilities |
US8167939B2 (en) | 2009-01-28 | 2012-05-01 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US8377122B2 (en) | 2009-01-28 | 2013-02-19 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US10531983B2 (en) | 2009-01-28 | 2020-01-14 | Novartis Ag | Ocular implant with stiffness qualities, methods of implantation and system |
US8574294B2 (en) | 2009-01-28 | 2013-11-05 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US8172899B2 (en) | 2009-01-28 | 2012-05-08 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US8262726B2 (en) | 2009-01-28 | 2012-09-11 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US11344448B2 (en) | 2009-01-28 | 2022-05-31 | Alcon Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US9763828B2 (en) | 2009-01-28 | 2017-09-19 | Novartis Ag | Ocular implant with stiffness qualities, methods of implantation and system |
US11839571B2 (en) | 2009-01-28 | 2023-12-12 | Alcon Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US9549846B2 (en) | 2009-12-23 | 2017-01-24 | Novartis Ag | Drug delivery devices and methods |
US9089392B2 (en) | 2009-12-23 | 2015-07-28 | Transcend Medical, Inc. | Drug delivery devices and methods |
US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
US9326891B2 (en) | 2010-11-15 | 2016-05-03 | Aquesys, Inc. | Methods for deploying intraocular shunts |
US9017276B2 (en) | 2010-11-15 | 2015-04-28 | Aquesys, Inc. | Shunt placement through the sclera |
US8663303B2 (en) | 2010-11-15 | 2014-03-04 | Aquesys, Inc. | Methods for deploying an intraocular shunt from a deployment device and into an eye |
US8585629B2 (en) | 2010-11-15 | 2013-11-19 | Aquesys, Inc. | Systems for deploying intraocular shunts |
US8852137B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for implanting a soft gel shunt in the suprachoroidal space |
US10307293B2 (en) | 2010-11-15 | 2019-06-04 | Aquesys, Inc. | Methods for intraocular shunt placement |
US8801766B2 (en) | 2010-11-15 | 2014-08-12 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US9980854B2 (en) | 2010-11-15 | 2018-05-29 | Aquesys, Inc. | Shunt placement through the sclera |
US8852256B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for intraocular shunt placement |
US10842671B2 (en) | 2010-11-15 | 2020-11-24 | Aquesys, Inc. | Intraocular shunt placement in the suprachoroidal space |
US8758290B2 (en) | 2010-11-15 | 2014-06-24 | Aquesys, Inc. | Devices and methods for implanting a shunt in the suprachoroidal space |
US10004638B2 (en) | 2010-11-15 | 2018-06-26 | Aquesys, Inc. | Intraocular shunt delivery |
US8721702B2 (en) | 2010-11-15 | 2014-05-13 | Aquesys, Inc. | Intraocular shunt deployment devices |
US8974511B2 (en) | 2010-11-15 | 2015-03-10 | Aquesys, Inc. | Methods for treating closed angle glaucoma |
US9095411B2 (en) | 2010-11-15 | 2015-08-04 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US8828070B2 (en) | 2010-11-15 | 2014-09-09 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US8308701B2 (en) | 2010-11-15 | 2012-11-13 | Aquesys, Inc. | Methods for deploying intraocular shunts |
US10307292B2 (en) | 2011-07-18 | 2019-06-04 | Mor Research Applications Ltd | Device for adjusting the intraocular pressure |
US9883969B2 (en) | 2011-12-08 | 2018-02-06 | Aquesys, Inc. | Intrascleral shunt placement |
US8852136B2 (en) | 2011-12-08 | 2014-10-07 | Aquesys, Inc. | Methods for placing a shunt into the intra-scleral space |
US10080682B2 (en) | 2011-12-08 | 2018-09-25 | Aquesys, Inc. | Intrascleral shunt placement |
US8765210B2 (en) | 2011-12-08 | 2014-07-01 | Aquesys, Inc. | Systems and methods for making gelatin shunts |
US10271989B2 (en) | 2012-03-26 | 2019-04-30 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US11197780B2 (en) | 2012-03-26 | 2021-12-14 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US9554940B2 (en) | 2012-03-26 | 2017-01-31 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US11944573B2 (en) | 2012-03-26 | 2024-04-02 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
US9907697B2 (en) | 2012-04-24 | 2018-03-06 | Novartis Ag | Delivery system for ocular implant |
US10912676B2 (en) | 2012-04-24 | 2021-02-09 | Alcon Inc. | Delivery system for ocular implant |
US9155656B2 (en) | 2012-04-24 | 2015-10-13 | Transcend Medical, Inc. | Delivery system for ocular implant |
US9480598B2 (en) | 2012-09-17 | 2016-11-01 | Novartis Ag | Expanding ocular implant devices and methods |
US9763829B2 (en) | 2012-11-14 | 2017-09-19 | Novartis Ag | Flow promoting ocular implant |
US10195078B2 (en) | 2013-02-19 | 2019-02-05 | Aquesys, Inc. | Adjustable intraocular flow regulation |
US10195079B2 (en) | 2013-02-19 | 2019-02-05 | Aquesys, Inc. | Adjustable intraocular implant |
US10524959B2 (en) | 2013-02-27 | 2020-01-07 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
US9610195B2 (en) | 2013-02-27 | 2017-04-04 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US11559430B2 (en) | 2013-03-15 | 2023-01-24 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US10285853B2 (en) | 2013-03-15 | 2019-05-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US11523938B2 (en) | 2013-03-15 | 2022-12-13 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US10188551B2 (en) | 2013-03-15 | 2019-01-29 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
US10369048B2 (en) | 2013-06-28 | 2019-08-06 | Aquesys, Inc. | Intraocular shunt implantation |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11612517B2 (en) | 2015-06-03 | 2023-03-28 | Aquesys, Inc. | Ab externo intraocular shunt placement |
US10470927B2 (en) | 2015-06-03 | 2019-11-12 | Aquesys, Inc. | AB externo intraocular shunt placement |
US10463537B2 (en) | 2015-06-03 | 2019-11-05 | Aquesys Inc. | Ab externo intraocular shunt placement |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
US11376040B2 (en) | 2017-10-06 | 2022-07-05 | Glaukos Corporation | Systems and methods for delivering multiple ocular implants |
USD938585S1 (en) | 2017-10-27 | 2021-12-14 | Glaukos Corporation | Implant delivery apparatus |
USD901683S1 (en) | 2017-10-27 | 2020-11-10 | Glaukos Corporation | Implant delivery apparatus |
USD846738S1 (en) | 2017-10-27 | 2019-04-23 | Glaukos Corporation | Implant delivery apparatus |
US11246753B2 (en) | 2017-11-08 | 2022-02-15 | Aquesys, Inc. | Manually adjustable intraocular flow regulation |
US11223960B2 (en) | 2020-05-13 | 2022-01-11 | T-Mobile Usa, Inc. | Network planning tool for forecasting in telecommunications networks |
US10880754B1 (en) | 2020-05-13 | 2020-12-29 | T-Mobile Usa, Inc. | Network planning tool for retention analysis in telecommunications networks |
Also Published As
Publication number | Publication date |
---|---|
US5968058A (en) | 1999-10-19 |
US6468283B1 (en) | 2002-10-22 |
US20040088048A1 (en) | 2004-05-06 |
US7481816B2 (en) | 2009-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7481816B2 (en) | Intraocular implant, delivery device, and method of implantation | |
US5868697A (en) | Intraocular implant | |
US5702414A (en) | Method of implanting an intraocular implant | |
US7670310B2 (en) | Flow regulating implants | |
US8313454B2 (en) | Fluid drainage device, delivery device, and associated methods of use and manufacture | |
CA2576117C (en) | Delivery device for intraocular implant | |
CA2220355C (en) | Intraocular implant, delivery device, and method of implantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |